ATE293123T1 - Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga - Google Patents

Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga

Info

Publication number: ATE293123T1
Authority: AT; Austria
Prior art keywords: applications; nucleoside; nucleotide; well; oligonucleotides
Prior art date: 1997-09-12

Application number

AT98942516T

Other languages

English (en)

Inventor

Jesper Wengel

Poul Nielsen

Original Assignee

Exiqon As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-12

Filing date

1998-09-14

Publication date

2005-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27570781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293123(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-14 Application filed by Exiqon As filed Critical Exiqon As

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE293123T1 publication Critical patent/ATE293123T1/de

Links

108091034117 Oligonucleotide Chemical class 0.000 title abstract 3
239000002773 nucleotide Chemical class 0.000 title abstract 2
HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical class C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 title abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
108020004635 Complementary DNA Proteins 0.000 abstract 1
108020004394 Complementary RNA Proteins 0.000 abstract 1
-1 LNA modified oligonucleotides Chemical class 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
239000003184 complementary RNA Substances 0.000 abstract 1
238000006073 displacement reaction Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
239000002777 nucleoside Substances 0.000 abstract 1
150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT98942516T 1997-09-12 1998-09-14 Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga ATE293123T1 (de)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
DK105497		1997-09-12
DK149297		1997-12-19
DK6198		1998-01-16
DK28698		1998-03-03
DK58598		1998-04-29
US8830998P	1998-06-05	1998-06-05
DK75098		1998-06-08
DKPA199800982		1998-07-28
PCT/DK1998/000393 WO1999014226A2 (en)	1997-09-12	1998-09-14	Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues

Publications (1)

Publication Number	Publication Date
ATE293123T1 true ATE293123T1 (de)	2005-04-15

Family

ID=27570781

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98942516T ATE293123T1 (de)	1997-09-12	1998-09-14	Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga

Country Status (12)

Country	Link
EP (5)	EP2341058A3 (de)
JP (2)	JP4236812B2 (de)
KR (1)	KR100414936B1 (de)
CN (1)	CN1273476C (de)
AT (1)	ATE293123T1 (de)
AU (1)	AU9063398A (de)
CA (1)	CA2303299C (de)
DE (2)	DE69829760T3 (de)
ES (1)	ES2242291T5 (de)
IL (5)	IL135000A0 (de)
NZ (1)	NZ503765A (de)
WO (1)	WO1999014226A2 (de)

Families Citing this family (1143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
USRE44779E1 (en)	1997-03-07	2014-02-25	Santaris Pharma A/S	Bicyclonucleoside and oligonucleotide analogues
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6583168B1 (en)	1997-11-25	2003-06-24	Applera Corporation	Sulfonated diarylrhodamine dyes
US6833361B2 (en)	1998-05-26	2004-12-21	Ribapharm, Inc.	Nucleosides having bicyclic sugar moiety
CA2333380A1 (en)	1998-05-26	1999-12-02	Icn Pharmaceuticals, Inc.	Novel nucleosides having bicyclic sugar moiety
JP2003511466A (ja) *	1998-11-11	2003-03-25	パンセコ・アクティーゼルスカブ	修飾ｐｎａ分子
US6548651B1 (en)	1998-11-11	2003-04-15	Pantheco A/S	Modified peptide nucleic acid (PNA) molecules
JP4148662B2 (ja) *	2000-08-10	2008-09-10	第一三共株式会社	ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
CZ296576B6 (cs)	1999-02-12	2006-04-12	Sankyo Company Limited	Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
CN1350542A (zh) *	1999-03-18	2002-05-22	埃克西库恩公司	木－lna类似物
US7084125B2 (en)	1999-03-18	2006-08-01	Exiqon A/S	Xylo-LNA analogues
RU2001128165A (ru)	1999-03-18	2004-03-27	Эксикон А/С (Dk)	Выявление мутаций в генах посредством специфичных lna-праймеров
ATE314488T1 (de)	1999-03-18	2006-01-15	Exiqon As	Einstufige probezubereitung und bestimmung von nukleinsäure in biologischen proben
US6734291B2 (en)	1999-03-24	2004-05-11	Exiqon A/S	Synthesis of [2.2.1]bicyclo nucleosides
JP4768132B2 (ja)	1999-03-24	2011-09-07	エクシコンエ／エス	［２．２．１］ビシクロヌクレオシドの改良された製法
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
EP1178999B1 (de) *	1999-05-04	2007-03-14	Santaris Pharma A/S	L-ribo-lna analoge
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides
DE19926154A1 (de)	1999-06-09	2000-12-14	Ktb Tumorforschungs Gmbh	Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
JP4151751B2 (ja)	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
IL148916A0 (en) *	1999-10-04	2002-09-12	Exiqon As	Design of high affinity rnase h recruiting oligonucleotide
AU7406600A (en) *	1999-10-04	2001-05-10	Exiqon A/S	A method of increasing the specificity of oxy-lna oligonucleotides
US20020068709A1 (en) *	1999-12-23	2002-06-06	Henrik Orum	Therapeutic uses of LNA-modified oligonucleotides
US8202979B2 (en)	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en)	2002-02-20	2012-09-25	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US6936467B2 (en) *	2000-03-27	2005-08-30	University Of Delaware	Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AP2002002638A0 (en) *	2000-03-27	2002-09-30	Univ Delaware	Targeted chromosomal genomic alternations with modified single stranded oligonucleotides.
PT1309726E (pt)	2000-03-30	2010-03-08	Whitehead Biomedical Inst	Mediadores de interferência por rna específicos de sequência de rna
US6887664B2 (en)	2000-06-06	2005-05-03	Applera Corporation	Asynchronous primed PCR
JP2002322192A (ja) *	2000-08-10	2002-11-08	Sankyo Co Ltd	２’−ｏ，４’−ｃ−架橋ヌクレオシドトリリン酸体
JP4413493B2 (ja)	2000-10-04	2010-02-10	サンタリスファーマアー／エス	プリンｌｎａ類似体の改善された合成方法
AU1312502A (en)	2000-10-11	2002-04-22	Pe Corp Ny	Fluorescent nucleobase conjugates having anionic linkers
US20040259247A1 (en)	2000-12-01	2004-12-23	Thomas Tuschl	Rna interference mediating small rna molecules
US6720148B1 (en)	2001-02-22	2004-04-13	Caliper Life Sciences, Inc.	Methods and systems for identifying nucleotides by primer extension
US20030077609A1 (en) *	2001-03-25	2003-04-24	Jakobsen Mogens Havsteen	Modified oligonucleotides and uses thereof
WO2002079495A2 (en)	2001-03-27	2002-10-10	University Of Delaware	Genomics applications for modified oligonucleotides
WO2002079467A2 (en) *	2001-03-29	2002-10-10	Københavns Universitet	Antibiotic-free bacterial strain selection with antisense molecules
EP1251183A3 (de) *	2001-04-18	2003-12-10	Exiqon A/S	Verbesserte Helfersonden zur Detektion einer Zielsequenz mittels Fangoligonukleotid
US7109165B2 (en)	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US20050148530A1 (en)	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en)	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002317437A1 (en) *	2001-05-18	2002-12-03	Cureon A/S	Therapeutic uses of lna-modified oligonucleotides in infectious diseases
WO2005078097A2 (en)	2004-02-10	2005-08-25	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
US20030032028A1 (en) *	2001-06-12	2003-02-13	Gayle Dace	In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads
WO2002101041A1 (en) *	2001-06-12	2002-12-19	Takara Bio Inc.	Method of amplifying nucleic acid and method of detecting nucleotide polymorphism with the use of nucleotide analog
US7053195B1 (en)	2001-06-12	2006-05-30	Syngenta Participatious Ag	Locked nucleic acid containing heteropolymers and related methods
GB0114719D0 (en) *	2001-06-15	2001-08-08	Glaxo Group Ltd	Compound
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2790034A1 (en)	2001-06-21	2003-01-03	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7153954B2 (en)	2001-07-12	2006-12-26	Santaris Pharma A/S	Method for preparation of LNA phosphoramidites
EP2345720A3 (de)	2001-07-12	2012-01-25	University of Massachusetts	In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US6822088B2 (en)	2001-07-17	2004-11-23	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides on solid support
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
AU2002334307A1 (en)	2001-09-04	2003-03-18	Exiqon A/S	Novel lna compositions and uses thereof
EP1487877B1 (de)	2001-09-18	2010-10-27	Genentech, Inc.	Zusammensetzungen und verfahren für die diagnose von tumoren
US7414111B2 (en)	2001-09-19	2008-08-19	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
US7306906B2 (en)	2001-09-19	2007-12-11	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
EP1446503A2 (de)	2001-09-27	2004-08-18	University Of Delaware	Zusammensetzung und verfahren zur verbesserung der oligonukleotidgesteuerten veränderung von nukleinsäuresequenzen
US7468244B2 (en)	2001-09-27	2008-12-23	University Of Delaware	Polymorphism detection and separation
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en)	2001-10-09	2011-08-26	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003033696A1 (en) *	2001-10-18	2003-04-24	Sankyo Company, Limited	Vegf antisense compound
WO2003088808A2 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2002351077A1 (en) *	2001-11-05	2003-05-19	Exiqon A/S	Oligonucleotides modified with novel alpha-l-rna analogues
JP2005508196A (ja)	2001-11-07	2005-03-31	アプレラコーポレイション	核酸分析の汎用ヌクレオチド
AU2002362013B2 (en)	2001-11-21	2008-04-24	Applied Biosystems, Llc.	Digital assay
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
AU2002366391A1 (en) *	2001-12-19	2003-06-30	Quantibact A/S	A method and a kit for determination of a microbial count
NZ533933A (en)	2002-01-02	2008-06-30	Genentech Inc	Compositions and methods for the diagnosis and treatment of glioma tumor
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ATE458047T1 (de)	2002-03-07	2010-03-15	Univ Delaware	Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
WO2003085110A2 (en)	2002-04-05	2003-10-16	Santaris Pharma A/S	Oligomeric compounds for the modulation hif-1alpha expression
US7569575B2 (en)	2002-05-08	2009-08-04	Santaris Pharma A/S	Synthesis of locked nucleic acid derivatives
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040014957A1 (en) *	2002-05-24	2004-01-22	Anne Eldrup	Oligonucleotides having modified nucleoside units
AU2003241621A1 (en) *	2002-05-24	2003-12-12	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
AU2003248708A1 (en) *	2002-06-17	2003-12-31	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US7005265B1 (en)	2002-06-20	2006-02-28	Wenhong Fan	Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays
EP1527175B1 (de) *	2002-06-24	2009-05-27	Exiqon A/S	Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen
FI20021325A0 (fi)	2002-07-05	2002-07-05	Valtion Teknillinen	Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi
US7956176B2 (en)	2002-09-05	2011-06-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP2330194A3 (de)	2002-09-13	2011-10-12	Replicor, Inc.	Nicht-sequenzkomplementäre antivirale Oligonukleotide
US7229976B2 (en)	2002-09-26	2007-06-12	Isis Pharmaceuticals, Inc.	Modulation of forkhead box O1A expression
WO2004035819A2 (en) *	2002-10-21	2004-04-29	Exiqon A/S	Oligonucleotide analogues for detecting and analyzing nucleic acids
US20040219565A1 (en)	2002-10-21	2004-11-04	Sakari Kauppinen	Oligonucleotides useful for detecting and analyzing nucleic acids of interest
CA2504694C (en) *	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
US9045518B2 (en)	2002-11-18	2015-06-02	Santaris Pharma A/S	Amino-LNA, thio-LNA and alpha-L-oxy-LN
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
JP4777777B2 (ja)	2002-11-25	2011-09-21	雅文松尾	ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
US20040115634A1 (en)	2002-12-11	2004-06-17	Isis Pharmaceuticals, Inc.	Modulation of stat 6 expression
US7713738B2 (en)	2003-02-10	2010-05-11	Enzon Pharmaceuticals, Inc.	Oligomeric compounds for the modulation of survivin expression
PT1592793E (pt)	2003-02-10	2009-09-30	Santaris Pharma As	Compostos oligoméricos para a modulação da expressão de survivina
WO2004072284A1 (en)	2003-02-11	2004-08-26	Antisense Therapeutics Ltd	Modulation of insulin like growth factor i receptor expression
WO2004074503A2 (en) *	2003-02-21	2004-09-02	Hoser Mark J	Nucleic acid sequencing methods, kits and reagents
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2519860C (en)	2003-03-21	2018-01-16	Santaris Pharma A/S	Short interfering rna (sirna) analogues
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
WO2004096124A2 (en)	2003-04-01	2004-11-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
EP1641936B1 (de)	2003-06-17	2010-08-04	Human Genetic Signatures PTY Ltd.	Verfahren zur genomamplifikation
US20050089889A1 (en)	2003-06-20	2005-04-28	Ramsing Niels B.	Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
EP1661905B9 (de)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
DE602004018801D1 (de)	2003-09-04	2009-02-12	Human Genetic Signatures Pty	Nukleinsäurenachweistest
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
KR100750788B1 (ko)	2003-09-18	2007-08-20	아이시스 파마수티컬즈 인코포레이티드	ｅＩＦ4Ｅ 발현의 조정
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
DE602004015832D1 (de)	2003-11-07	2008-09-25	Daiichi Sankyo Co Ltd	Verfahren zum nachweis von genetischem polymorphismus
US7439341B2 (en)	2003-11-14	2008-10-21	Integrated Dna Technologies, Inc.	Fluorescence quenching azo dyes, their methods of preparation and use
SI2295073T1 (sl)	2003-11-17	2014-07-31	Genentech, Inc.	Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
DK1538154T3 (da)	2003-11-20	2009-03-02	Exiqon As	Quencher-sammensætninger, der indeholder anthraquinon-enheder
RU2377301C2 (ru)	2003-12-23	2009-12-27	Сантарис Фарма А/С	ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
US20050164271A1 (en)	2004-01-20	2005-07-28	Sanjay Bhanot	Modulation of glucocorticoid receptor expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
US20070265220A1 (en) *	2004-03-15	2007-11-15	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8192937B2 (en)	2004-04-07	2012-06-05	Exiqon A/S	Methods for quantification of microRNAs and small interfering RNAs
AU2005238034A1 (en)	2004-04-23	2005-11-10	The Trustees Of Columbia University In The City Of New York	Inhibition of hairless protein mRNA
US8168777B2 (en)	2004-04-29	2012-05-01	Human Genetic Signatures Pty. Ltd.	Bisulphite reagent treatment of nucleic acid
US20050287558A1 (en)	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
EP1794173B1 (de)	2004-09-10	2010-08-04	Human Genetic Signatures PTY Ltd	Amplifikationsblocker umfassend interkalierende nukleinsäuren (ina) enthaltend interkalierende pseudonukleotide (ipn)
CN101258220A (zh)	2004-09-16	2008-09-03	阿普里拉股份有限公司	荧光染料化合物，共轭物及其应用
AU2005304112B2 (en)	2004-11-09	2009-06-04	Roche Innovation Center Copenhagen A/S	Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR20070095882A (ko)	2004-11-09	2007-10-01	산타리스 팔마 에이/에스	Ｌｎａ 올리고뉴클레오티드 및 암의 치료
US9447138B2 (en)	2004-11-09	2016-09-20	Roche Innovation Center Copenhagen A/S	Potent LNA oligonucleotides for the inhibition of HIF-1a expression
NZ555620A (en)	2004-12-03	2008-08-29	Human Genetic Signatures Pty	Methods for simplifying microbial nucleic acids by chemical modification of cytosines
WO2006069584A2 (en)	2004-12-29	2006-07-06	Exiqon A/S	NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
AU2006204006A1 (en)	2005-01-06	2006-07-13	Applera Corporation	Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
EP1869076A2 (de)	2005-03-10	2007-12-26	Genentech, Inc.	Verfahren und zusammensetzungen zur modulation der gefässintegrität
EP1871913A2 (de)	2005-03-25	2008-01-02	Ambion, Inc.	Verfahren und zusammensetzungen zur verringerung abundanter rna-transkripte
EP1866414B9 (de)	2005-03-31	2012-10-03	Calando Pharmaceuticals, Inc.	Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
EP2409980B1 (de)	2005-04-14	2015-06-03	Applied Biosystems, LLC	3'-modifizierte Oligonucleotide mit Pseudoisocytosin-Nukleobasederivaten und Anwendungen daraus als Primer oder Sonden
US7838502B2 (en)	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
AU2006246116A1 (en)	2005-05-11	2006-11-16	Aarhus Universitet	Method for diagnosis and treatment of a mental disease
WO2006124448A2 (en)	2005-05-11	2006-11-23	Vector Tobacco Inc.	Reduced risk tobacco products and methods of making same
JP2008545659A (ja)	2005-05-20	2008-12-18	インテグレイテッドディーエヌエイテクノロジーズインコーポレイテッド	オリゴヌクレオチドを標識する化合物及び方法
AU2006251496B2 (en) *	2005-05-25	2012-11-22	Tina Holding Aps	Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (TINA) and process for the preparation of TINA
CA2609218C (en)	2005-05-26	2016-10-11	Human Genetic Signatures Pty Ltd	Isothermal strand displacement amplification using primers containing a non-regular base
EP1891141B1 (de)	2005-05-31	2016-11-16	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007011901A2 (en)	2005-07-15	2007-01-25	Applera Corporation	Hot start reverse transcription by primer design
EP2308990B1 (de)	2005-07-15	2012-09-26	Life Technologies Corporation	Analyse von Boten-RNA und Mikro-RNA im gleichen Reaktionsansatz
CA2617693A1 (en)	2005-08-17	2007-02-22	Medexis S.A.	Composition and method for determination of ck19 expression
CA2620856C (en)	2005-08-29	2017-11-28	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
WO2007027894A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
WO2007026823A1 (ja) *	2005-08-31	2007-03-08	Osaka University	人工核酸プローブを用いた三重鎖核酸形成を基盤とした標的核酸の検出
US20070059713A1 (en)	2005-09-09	2007-03-15	Lee Jun E	SSB-DNA polymerase fusion proteins
CN101292046B (zh)	2005-09-14	2013-03-13	人类遗传标记控股有限公司	健康状态的测定法
EP2458011B1 (de)	2005-10-03	2013-07-24	Life Technologies Corporation	Zusammensetzungen, Verfahren und Kits zur Amplifikation von Nukleinsäuren
EP1971371B1 (de)	2005-12-01	2015-08-05	Pronai Therapeutics, Inc.	Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
DE602006018352D1 (de)	2005-12-06	2010-12-30	Ambion Inc	Rückübertragungs-primer und verfahren zu deren entwurf
WO2007073149A1 (en)	2005-12-22	2007-06-28	Keygene N.V.	Alternative nucleotides for improved targeted nucleotide exchange
US8288354B2 (en)	2005-12-28	2012-10-16	The Scripps Research Institute	Natural antisense and non-coding RNA transcripts as drug targets
EP1984499B1 (de)	2006-01-27	2015-05-27	Isis Pharmaceuticals, Inc.	Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulation von mikro-rnas
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
CA2913655A1 (en)	2006-01-27	2007-08-09	Biogen Ma Inc.	Nogo receptor antagonists
JP5342881B2 (ja) *	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
WO2007106690A2 (en)	2006-03-15	2007-09-20	Siemens Healthcare Diagnostics Inc.	Degenerate nucleobase analogs
US8133984B2 (en)	2006-03-16	2012-03-13	Pentabase Aps	Oligonucleotides comprising signalling pairs and hydrophobic nucleotides, stemless beacons, for detection of nucleic acids, methylation status and mutants of nucleic acids
WO2007107162A2 (en)	2006-03-23	2007-09-27	Santaris Pharma A/S	Small internally segmented interfering rna
CA2648132C (en)	2006-04-03	2019-05-28	Santaris Pharma A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2666859B1 (de)	2006-04-03	2019-01-02	Roche Innovation Center Copenhagen A/S	Pharmazeutische zusammensetzungen mit anti-mirna-antisense-oligonukleotiden
JP2009535642A (ja)	2006-05-03	2009-10-01	ゲイシンガークリニック	非アルコール性脂肪性肝炎（ｎａｓｈ）を診断及び予測する方法
EP2023940B1 (de)	2006-05-05	2011-06-22	Isis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der expression von sglt2
EP2505649A1 (de)	2006-05-05	2012-10-03	Isis Pharmaceuticals, Inc.	Verbindungen und Verfahren zur Modulation der Expression von GCGR
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
EP2049665A2 (de)	2006-07-28	2009-04-22	Applera Corporation	DINUKLEOTID-mRNA-CAP-ANALOGA
EP3305915B1 (de)	2006-08-01	2022-01-26	Applied Biosystems, LLC	Nachweis von analyten und nukleinsäuren
JP5560039B2 (ja)	2006-10-05	2014-07-23	マサチューセッツインスティテュートオブテクノロジー	ハイスループット分析のための多機能のコード化された粒子
WO2008049085A1 (en)	2006-10-18	2008-04-24	Isis Pharmaceuticals, Inc.	Antisense compounds
WO2008046911A2 (en)	2006-10-20	2008-04-24	Exiqon A/S	Novel human micrornas associated with cancer
WO2008052774A2 (en)	2006-10-31	2008-05-08	Noxxon Pharma Ag	Methods for detection of a single- or double-stranded nucleic acid molecule
US8420613B2 (en)	2006-11-15	2013-04-16	The J. David Gladstone Institutes	Methods and compositions for reducing amyloid beta levels
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
JP2010510807A (ja)	2006-11-27	2010-04-08	アイシスファーマシューティカルズ，インコーポレーテッド	高コレステロール血症を治療するための方法
US8293684B2 (en)	2006-11-29	2012-10-23	Exiqon	Locked nucleic acid reagents for labelling nucleic acids
EP3536788A1 (de)	2006-12-21	2019-09-11	QIAGEN GmbH	Mikro-rna-zielortblockierende oligos und verwendungen davon
WO2008086807A2 (en) *	2007-01-19	2008-07-24	Exiqon A/S	Mediated cellular delivery of lna oligonucleotides
US8507200B2 (en)	2007-02-09	2013-08-13	Northwestern University	Particles for detecting intracellular targets
CA2681406A1 (en)	2007-03-22	2008-09-25	Santaris Pharma A/S	Rna antagonist compounds for the inhibition of apo-b100 expression
WO2008113832A2 (en)	2007-03-22	2008-09-25	Santaris Pharma A/S	SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
CN101679979A (zh)	2007-03-24	2010-03-24	基酶有限公司	施用与人载脂蛋白b互补的反义寡核苷酸
US8999634B2 (en)	2007-04-27	2015-04-07	Quest Diagnostics Investments Incorporated	Nucleic acid detection combining amplification with fragmentation
JP5634862B2 (ja)	2007-05-16	2014-12-03	カーテーベートゥモーアフォルシュングスゲゼルシャフトミットベシュレンクテルハフツング	低粘度アントラサイクリン製剤
DK2160464T3 (da)	2007-05-30	2014-08-04	Univ Northwestern	Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
EP2170917B1 (de) *	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
US9598724B2 (en)	2007-06-01	2017-03-21	Ibis Biosciences, Inc.	Methods and compositions for multiple displacement amplification of nucleic acids
US7807372B2 (en)	2007-06-04	2010-10-05	Northwestern University	Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
ES2798758T3 (es)	2007-06-06	2020-12-14	Sarepta Therapeutics Inc	Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
CA2692579C (en) †	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
EP2183379B1 (de)	2007-08-01	2015-04-15	Dana Farber Cancer Institute	Anreicherung einer zielsequenz
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
WO2009027978A1 (en)	2007-08-30	2009-03-05	Hadasit Medical Research Services & Development Ltd.	NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
DK2548962T3 (en)	2007-09-19	2016-04-11	Applied Biosystems Llc	Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
AU2008307482B2 (en)	2007-10-02	2012-07-12	Amgen Inc.	Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
AU2008306455C1 (en)	2007-10-03	2014-04-17	Quark Pharmaceuticals, Inc.	Novel siRNA structures
EP2623599B1 (de)	2007-10-04	2019-01-02	Roche Innovation Center Copenhagen A/S	Mikromir-Moleküle
EP2212437A4 (de)	2007-11-07	2011-09-28	Univ British Columbia	Mikrofluidische vorrichtung und verfahren zu ihrer anwendung
CN102076852A (zh)	2007-11-09	2011-05-25	Isis药物公司	因子7表达的调节
US20110059895A1 (en)	2007-11-09	2011-03-10	Isis Pharmaceuticals, Inc.	Modulation of factor 9 expression
US8017338B2 (en)	2007-11-20	2011-09-13	Life Technologies Corporation	Reversible di-nucleotide terminator sequencing
JP5431351B2 (ja)	2007-11-27	2014-03-05	ヒューマンジェネティックシグネチャーズピーティーワイリミテッド	バイサルファイト修飾された核酸を増幅およびコピーするための酵素
US10365224B2 (en)	2007-12-06	2019-07-30	Genalyte, Inc.	Label-free optical sensors
EP2268811A1 (de)	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8227431B2 (en)	2008-03-17	2012-07-24	Hetero Drugs Limited	Nucleoside derivatives
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
DK2285819T3 (da)	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
CN102037123A (zh)	2008-04-04	2011-04-27	卡兰多制药股份有限公司	Epas1抑制剂的组合物和用途
US8846639B2 (en)	2008-04-04	2014-09-30	Isis Pharmaceutical, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US8278287B2 (en)	2008-04-15	2012-10-02	Quark Pharmaceuticals Inc.	siRNA compounds for inhibiting NRF2
AU2009237577B2 (en)	2008-04-18	2014-06-05	Baxter Healthcare Sa	Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2009143387A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc.	Modulation of smrt expression
EP2291200A4 (de)	2008-05-22	2012-05-30	Isis Pharmaceuticals Inc	Verfahren zur modulierung der expression von rbp4
EP2636756B2 (de)	2008-05-27	2019-11-20	Dako Denmark A/S	Zusammensetzungen und Verfahren zur Erkennung von chromosomalen Abweichungen mit neuen Hybridisierungspuffern
CA2726052A1 (en)	2008-06-04	2009-12-10	The Board Of Regents Of The University Of Texas System	Modulation of gene expression through endogenous small rna targeting of gene promoters
JP5524189B2 (ja)	2008-06-06	2014-06-18	クォークファーマシューティカルズインコーポレーティッド	耳障害治療のための組成物および方法
WO2010014592A1 (en)	2008-07-29	2010-02-04	The Board Of Regents Of The University Of Texas Sytem	Selective inhibition of polyglutamine protein expression
EP2333059A4 (de) *	2008-07-30	2013-01-09	Nippon Steel Kankyo Engineering Co Ltd	Universelles nukleinsäuresondenset und anwendungsvefahren dafür
ES2541442T3 (es)	2008-08-01	2015-07-20	Roche Innovation Center Copenhagen A/S	Modulación mediada por microARN de factores estimulantes de colonias
JP5357883B2 (ja) *	2008-08-22	2013-12-04	独立行政法人科学技術振興機構	新規核酸誘導体およびそれを用いたヌクレアーゼ耐性核酸の調製方法
NZ601660A (en)	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3375451A1 (de)	2008-08-25	2018-09-19	Excaliard Pharmaceuticals, Inc.	Verfahren zur verringerung der narbenbildung während der wundheilung mithilfe von ctgf-gerichteten antisense-verbindungen
US8583380B2 (en)	2008-09-05	2013-11-12	Aueon, Inc.	Methods for stratifying and annotating cancer drug treatment options
US8604192B2 (en)	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
MX2011004097A (es)	2008-10-15	2011-07-28	Isis Pharmaceuticals Inc	Modulacion de la expresion del factor 11.
EP2358398A2 (de)	2008-10-24	2011-08-24	Isis Pharmaceuticals, Inc.	Oligomere verbindungen und verfahren
WO2010048549A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US9846126B2 (en)	2008-10-27	2017-12-19	Genalyte, Inc.	Biosensors based on optical probing and sensing
CN106955360A (zh)	2008-11-24	2017-07-18	西北大学	多价rna纳米颗粒组合物
RU2620970C2 (ru)	2008-12-04	2017-05-30	КьюРНА,Инк.,	Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
CN102361985B (zh)	2008-12-04	2017-06-20	库尔纳公司	通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
WO2010080452A2 (en)	2008-12-18	2010-07-15	Quark Pharmaceuticals, Inc.	siRNA COMPOUNDS AND METHODS OF USE THEREOF
EP2376637A1 (de)	2008-12-22	2011-10-19	Keygene N.V.	Verwendung von doppelstrang-rna zur erhöhung der wirksamkeit einer zielgenänderung in pflanzenprotoplasten
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2750379A1 (en)	2009-01-14	2010-07-22	Gordon J. Lutz	Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
AU2010207826B2 (en)	2009-02-02	2013-10-03	Qiagen Gmbh	Method for quantification of small RNA species
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
WO2010093904A2 (en)	2009-02-12	2010-08-19	Curna, Inc.	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2401396B1 (de)	2009-02-26	2016-11-23	Dako Denmark A/S	Verfahren zur durchführung eines stringenten waschschritts bei hybridisierungsanwendungen
EP2408796B1 (de)	2009-03-16	2020-04-22	Ionis Pharmaceuticals, Inc.	Targeting Apolipoprotein B für die Reduktion von Apolipoprotein C-III
EP2408919B1 (de)	2009-03-16	2017-10-18	CuRNA, Inc.	Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
CA2755404C (en)	2009-03-17	2020-03-24	Curna, Inc.	Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010120524A2 (en)	2009-03-31	2010-10-21	Altair Therapeutics, Inc.	Methods of modulating an immune response to a viral infection
EP2419535B1 (de)	2009-04-15	2022-08-17	Northwestern University	Freisetzung von oligonukleotid-funktionalisierten nanopartikeln
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
ES2599979T3 (es)	2009-04-24	2017-02-06	Roche Innovation Center Copenhagen A/S	Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2421972A2 (de)	2009-04-24	2012-02-29	The Board of Regents of The University of Texas System	Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
KR101722541B1 (ko)	2009-05-06	2017-04-04	큐알엔에이, 인크.	Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
CN102459596B (zh)	2009-05-06	2016-09-07	库尔纳公司	通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010135329A2 (en)	2009-05-18	2010-11-25	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
EP3597657B1 (de)	2009-05-21	2021-09-01	Siemens Healthcare Diagnostics Inc.	Universaletiketten mit nichtnatürlichen nukleobasen
CA2762987A1 (en)	2009-05-22	2010-11-25	Joseph Collard	Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
CN102458418B (zh)	2009-06-08	2015-09-16	夸克制药公司	一种寡核苷酸化合物的制药用途
CA2765700C (en)	2009-06-16	2021-01-05	Opko Curna, Llc	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (es)	2009-06-16	2017-08-08	Curna, Inc.	Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
ES2618894T3 (es)	2009-06-24	2017-06-22	Curna, Inc.	Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
JP2011024434A (ja)	2009-07-22	2011-02-10	Galaxy Pharma Inc	オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー
US20120252869A1 (en)	2009-07-24	2012-10-04	Opko Curna, Llc	Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011012136A1 (en)	2009-07-28	2011-02-03	Exiqon A/S	A method for classifying a human cell sample as cancerous
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
ES2599986T3 (es)	2009-08-11	2017-02-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
CN102482670B (zh)	2009-08-21	2018-06-15	库尔纳公司	通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
EP3626823A1 (de)	2009-09-11	2020-03-25	Ionis Pharmaceuticals, Inc.	Modulation der huntingtin-expression
DK2480669T3 (en)	2009-09-25	2018-02-12	Curna Inc	TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
ES2628739T3 (es)	2009-10-15	2017-08-03	Ibis Biosciences, Inc.	Amplificación por desplazamiento múltiple
US8697386B2 (en)	2009-10-22	2014-04-15	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
CA2778532A1 (en)	2009-10-27	2011-05-12	Swift Biosciences, Inc.	Polynucleotide primers and probes
DK2494075T3 (en)	2009-10-30	2018-07-23	Univ Northwestern	TABLE-MANAGED NANOCONJUGATES
US20110110860A1 (en)	2009-11-02	2011-05-12	The Board Of Regents Of The University Of Texas System	Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
KR20120102674A (ko)	2009-11-03	2012-09-18	유니버시티 오브 버지니아 페이턴트 파운데이션	중합체 분석물을 검출하는 다용도의 가시적인 방법
EP2504450B1 (de)	2009-11-23	2016-07-06	Swift Biosciences, Inc.	Vorrichtung zur erweiterung von einsträngigen zielmolekülen
BR112012012750A2 (pt)	2009-11-30	2020-08-11	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado e método
US20130040294A1 (en)	2009-12-02	2013-02-14	Steen H. Matthiesen	Compositions and methods for performing hybridizations with no denaturation
KR101718534B1 (ko)	2009-12-09	2017-03-22	닛토덴코 가부시키가이샤	Ｈｓｐ４７ 발현의 조절
EP2510098B1 (de)	2009-12-09	2015-02-11	Quark Pharmaceuticals, Inc.	Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des zns
CA2782366A1 (en)	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
NO2516648T3 (de)	2009-12-23	2018-04-07
RU2619185C2 (ru)	2009-12-23	2017-05-12	Курна, Инк.	Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
US8962585B2 (en)	2009-12-29	2015-02-24	Curna, Inc.	Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
US8921334B2 (en)	2009-12-29	2014-12-30	Curna, Inc.	Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
DK2519632T3 (en)	2009-12-31	2018-07-23	Curna Inc	TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
DK2521784T3 (en)	2010-01-04	2018-03-12	Curna Inc	TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
WO2011084193A1 (en)	2010-01-07	2011-07-14	Quark Pharmaceuticals, Inc.	Oligonucleotide compounds comprising non-nucleotide overhangs
US8653047B2 (en)	2010-01-08	2014-02-18	Isis Pharmaceuticals, Inc.	Modulation of angiopoietin-like 3 expression
KR101854926B1 (ko)	2010-01-11	2018-05-04	큐알엔에이, 인크.	성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
DK2529015T3 (en)	2010-01-25	2018-02-26	Curna Inc	TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
WO2011097388A1 (en)	2010-02-03	2011-08-11	Alnylam Pharmaceuticals, Inc.	Selective inhibition of polyglutamine protein expression
WO2011097643A1 (en)	2010-02-08	2011-08-11	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
EP3628750A1 (de)	2010-02-08	2020-04-01	Ionis Pharmaceuticals, Inc.	Selektive reduktion von allelvarianten
RU2608496C2 (ru)	2010-02-22	2017-01-18	Курна, Инк.	Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
TWI429453B (zh)	2010-02-23	2014-03-11	建南德克公司	抗tat419抗體及其用途
ES2631458T3 (es)	2010-03-04	2017-08-31	Interna Technologies B.V.	Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
CN102859003B (zh)	2010-03-08	2014-07-30	达纳-法伯癌症研究院有限公司	使用参考封闭序列的全cold-pcr富集
US20130101512A1 (en)	2010-03-12	2013-04-25	Chad A. Mirkin	Crosslinked polynucleotide structure
WO2011115817A1 (en)	2010-03-16	2011-09-22	Isis Pharmaceuticals, Inc.	Methods of preparing 2'-o-substituted purine nucleosides
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
US8889350B2 (en)	2010-03-26	2014-11-18	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
AU2011230496B2 (en)	2010-03-26	2015-09-17	Integrated Dna Technologies, Inc.	Methods for enhancing nucleic acid hybridization
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
US8980856B2 (en)	2010-04-02	2015-03-17	Curna, Inc.	Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
KR101900962B1 (ko)	2010-04-09	2018-09-20	큐알엔에이, 인크.	섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
WO2011133695A2 (en)	2010-04-20	2011-10-27	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
KR101869570B1 (ko)	2010-04-28	2018-06-20	아이오니스 파마수티컬즈, 인코포레이티드	변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
RS56011B1 (sr)	2010-04-29	2017-09-29	Ionis Pharmaceuticals Inc	Modulacija ekspresije transtiretina
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
US9212390B2 (en)	2010-04-30	2015-12-15	Exiqon A/S	In situ hybridization method and buffer
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
RU2018110642A (ru)	2010-05-03	2019-02-27	Курна, Инк.	Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh)	2010-05-14	2017-06-11	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CA2799207C (en)	2010-05-26	2019-03-26	Curna, Inc.	Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
JP5917497B2 (ja)	2010-05-26	2016-05-18	カッパーアールエヌエー，インコーポレイテッド	メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療
WO2011150226A1 (en)	2010-05-26	2011-12-01	Landers James P	Method for detecting nucleic acids based on aggregate formation
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2576839B1 (de)	2010-06-07	2017-05-10	Firefly Bioworks, Inc.	Nukleinsäurenachweis und -quantifizierung durch posthybridisierungs-kennzeichnung und universelle kodierung
EP2580228B1 (de)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
EP2582397A4 (de)	2010-06-15	2014-10-29	Isis Pharmaceuticals Inc	Verbindungen und verfahren zur modulierung der interaktion zwischen proteinen und zielnukleinsäuren
WO2011163499A2 (en)	2010-06-23	2011-12-29	Opko Curna, Llc	Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
CN102959091A (zh)	2010-06-30	2013-03-06	三菱化学美迪恩斯株式会社	高灵敏度的突变基因检测方法
NZ704322A (en)	2010-07-06	2016-07-29	Interna Technologies Bv	Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CN103068982B (zh)	2010-07-14	2017-06-09	库尔纳公司	通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
EP2913402B1 (de)	2010-07-16	2017-10-18	Tocagen Inc.	Retrovirusdetektion
WO2012012467A2 (en)	2010-07-19	2012-01-26	Isis Pharmaceuticals, Inc.	Modulation of nuclear-retained rna
GB201012418D0 (en)	2010-07-23	2010-09-08	Santaris Pharma As	Process
WO2012027206A1 (en)	2010-08-24	2012-03-01	Merck Sharp & Dohme Corp.	SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
AU2011299233B2 (en)	2010-09-07	2016-09-15	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
EP2619215B1 (de)	2010-09-22	2018-09-05	Alios Biopharma, Inc.	Azido-nukleoside und nukleotidanaloga
US8481680B2 (en)	2010-10-05	2013-07-09	Genentech, Inc.	Mutant smoothened and methods of using the same
US8648053B2 (en)	2010-10-20	2014-02-11	Rosalind Franklin University Of Medicine And Science	Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
US9222088B2 (en)	2010-10-22	2015-12-29	Curna, Inc.	Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP3266881B1 (de)	2010-11-05	2019-12-25	Genalyte, Inc.	Systeme zur optischen analytdetektion und verfahren zur verwendung
WO2012064758A2 (en)	2010-11-08	2012-05-18	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
US10000752B2 (en)	2010-11-18	2018-06-19	Curna, Inc.	Antagonat compositions and methods of use
ES2657590T3 (es)	2010-11-23	2018-03-06	Curna, Inc.	Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
AU2011337323B2 (en)	2010-12-02	2015-11-26	Keygene N.V.	Targeted alteration of DNA
EP2646550B1 (de)	2010-12-02	2015-02-18	Keygene N.V.	Gezielte änderung von dna mit oligonukleotiden
EP2474617A1 (de)	2011-01-11	2012-07-11	InteRNA Technologies BV	MIR zur Behandlung von Neoangiogenese
MX340258B (es)	2011-01-11	2016-07-01	Seegene Inc	Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto.
DK2670404T3 (en)	2011-02-02	2018-11-19	Univ Princeton	CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
KR101697396B1 (ko)	2011-02-02	2017-01-17	엑스칼리아드 파마슈티컬즈, 인코포레이티드	결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
US10017764B2 (en)	2011-02-08	2018-07-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109495A1 (en)	2011-02-09	2012-08-16	Metabolic Solutions Development Company, Llc	Cellular targets of thiazolidinediones
WO2012113775A1 (en)	2011-02-21	2012-08-30	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
US9796979B2 (en)	2011-03-03	2017-10-24	Quark Pharmaceuticals Inc.	Oligonucleotide modulators of the toll-like receptor pathway
CN103562387A (zh)	2011-03-03	2014-02-05	夸克医药公司	Toll样受体途径的寡核苷酸调剂
CN103492572A (zh)	2011-03-03	2014-01-01	夸克医药公司	用于治疗肺疾病和损伤的组合物和方法
EP2495336B8 (de)	2011-03-04	2014-07-23	Roche Diagnostics GmbH	Neuer Typ von universellen Sonden zur Detektion von Genomvarianten
EP2691543B1 (de)	2011-03-29	2017-11-01	Seegene, Inc.	Erkennung von zielnukleinsäuresequenzen durch pto-spaltung und verlängerungsabhängige spaltung
EP3333269B1 (de)	2011-03-31	2021-05-05	Dana-Farber Cancer Institute, Inc.	Verfahren zur ermöglichung einer multiplex-kalt-pcr
JP5943993B2 (ja)	2011-04-01	2016-07-05	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節
EP2508607A1 (de)	2011-04-07	2012-10-10	Helmholtz-Zentrum für Infektionsforschung GmbH	Medikament zur Leberregeneration und zur Behandlung von Leberversagen
WO2012142458A1 (en)	2011-04-13	2012-10-18	Isis Pharmaceuticals, Inc.	Antisense modulation of ptp1b expression
PH12019502377A1 (en)	2011-04-21	2022-11-14	Isis Pharmaceuticals Inc	Modulation of hepatitis b virus (hbv) expression
US20140186844A1 (en)	2011-04-26	2014-07-03	Swift Biosciences, Inc.	Polynucleotide primers and probes
CN107854478A (zh)	2011-04-27	2018-03-30	Ionis制药公司	载脂蛋白ciii（apociii）表达的调节
WO2012149339A2 (en)	2011-04-29	2012-11-01	Sequenom, Inc.	Quantification of a minority nucleic acid species
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151324A1 (en)	2011-05-02	2012-11-08	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
WO2012150749A1 (en)	2011-05-04	2012-11-08	Seegene, Inc.	Detection of target nucleic acid sequences by po cleavage and hybridization
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2718439B1 (de)	2011-06-09	2017-08-09	CuRNA, Inc.	Behandlung von frataxin (fxn)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen fxn
US9315811B2 (en)	2011-06-10	2016-04-19	Ionis Pharmaceuticals, Inc.	Methods for modulating kallikrein (KLKB1) expression
WO2012170947A2 (en)	2011-06-10	2012-12-13	Isis Pharmaceuticals, Inc.	Methods for modulating factor 12 expression
WO2012174476A2 (en)	2011-06-16	2012-12-20	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
CA2840614A1 (en)	2011-06-29	2013-01-03	Isis Pharmaceuticals, Inc.	Methods for modulating kallikrein (klkb1) expression
ES2651514T3 (es)	2011-08-11	2018-01-26	Ionis Pharmaceuticals, Inc.	Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos
EP3453761A1 (de)	2011-08-29	2019-03-13	Ionis Pharmaceuticals, Inc.	Oligomer-konjugat-komplexe und deren verwendung
US9976138B2 (en)	2011-08-29	2018-05-22	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
WO2013033658A1 (en)	2011-09-02	2013-03-07	Northwestern University	Self-assembled nanostructures
KR101991980B1 (ko)	2011-09-06	2019-06-21	큐알엔에이, 인크.	소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
AU2011376698B2 (en)	2011-09-07	2014-07-17	Human Genetic Signatures Pty Ltd	Molecular detection assay
US9889209B2 (en)	2011-09-14	2018-02-13	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
ES2796556T3 (es)	2011-09-20	2020-11-27	Ionis Pharmaceuticals Inc	Modulación antisentido de la expresión de GCGR
WO2013046033A1 (en)	2011-09-30	2013-04-04	Dako Denmark A/S	Hybridization compositions and methods using formamide
EP2768974B1 (de)	2011-10-21	2017-07-19	Dako Denmark A/S	Hybridisierungszusammensetzungen und -verfahren
JP2015501155A (ja)	2011-10-25	2015-01-15	アイシスファーマシューティカルズ，インコーポレーテッド	Ｇｃｃｒ発現のアンチセンス調整
JP6118331B2 (ja)	2011-11-03	2017-04-19	クォークファーマシューティカルズインコーポレーティッドＱｕａｒｋＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	神経保護のための方法および組成物
EP3650544A1 (de)	2011-11-07	2020-05-13	Ionis Pharmaceuticals, Inc.	Modulation der tmprss6-expression
US9243291B1 (en)	2011-12-01	2016-01-26	Isis Pharmaceuticals, Inc.	Methods of predicting toxicity
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
AU2012353330B2 (en)	2011-12-16	2018-04-19	National University Corporation Tokyo Medical And Dental University	Chimeric double-stranded nucleic acid
UA117095C2 (uk)	2011-12-22	2018-06-25	Аліос Біофарма, Інк.	Нуклеозидна сполука або її фармацевтично прийнятна сіль
ES2673960T3 (es)	2011-12-22	2018-06-26	Ionis Pharmaceuticals, Inc.	Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
ES2886147T3 (es)	2011-12-22	2021-12-16	Interna Tech B V	MiARN para el tratamiento del cáncer de cabeza y de cuello
WO2013101645A1 (en)	2011-12-27	2013-07-04	The J. David Gladstone Institutes	Compositions and methods for regulating glucose metabolism
US20150025231A1 (en)	2012-01-11	2015-01-22	Cold Spring Harbor Laboratory	Compositions and methods for modulation of ikbkap splicing
EP2812342B1 (de)	2012-02-08	2017-11-15	Ionis Pharmaceuticals, Inc.	Modulation von rna durch wiederholtes targeting
JP5976849B2 (ja)	2012-03-05	2016-08-24	シージーンアイエヌシー	ＰＴＯ切断及び伸長アッセイによるターゲット核酸配列でのヌクレオチド変異検出｛ＤｅｔｅｃｔｉｏｎｏｆＮｕｃｌｅｏｔｉｄｅＶａｒｉａｔｉｏｎｏｎＴａｒｇｅｔＮｕｃｌｅｉｃＡｃｉｄＳｅｑｕｅｎｃｅｂｙＰＴＯＣｌｅａｖａｇｅａｎｄＥｘｔｅｎｓｉｏｎＡｓｓａｙ｝
EP2825885B1 (de)	2012-03-12	2021-05-12	The Board of Trustees of the University of Illinois	Optische analytdetektionssysteme mit magnetischer verstärkung
SG11201405669XA (en)	2012-03-13	2014-10-30	Swift Biosciences Inc	Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
US20150031750A1 (en)	2012-03-15	2015-01-29	The Scripps Research Institute	Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US9340784B2 (en)	2012-03-19	2016-05-17	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating alpha-1-antitrypsin expression
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
AU2013203395A1 (en)	2012-03-30	2013-10-17	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (de)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclische nukleinsäureanaloga
WO2013159108A2 (en)	2012-04-20	2013-10-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9133490B2 (en)	2012-05-16	2015-09-15	Transgenomic, Inc.	Step-up method for COLD-PCR enrichment
US20160002624A1 (en)	2012-05-17	2016-01-07	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide compositions
US9574193B2 (en)	2012-05-17	2017-02-21	Ionis Pharmaceuticals, Inc.	Methods and compositions for modulating apolipoprotein (a) expression
US9518261B2 (en)	2012-05-22	2016-12-13	Ionis Pharmaceuticals, Inc.	Modulation of enhancer RNA mediated gene expression
RU2748495C2 (ru)	2012-05-24	2021-05-26	Ионис Фармасьютикалз, Инк.	Способы и композиции для модулирования экспрессии аполипопротеина (а)
EP3241902B1 (de)	2012-05-25	2018-02-28	The Regents of The University of California	Verfahren und zusammensetzungen zur rna-gesteuerten ziel-dna-modifikation und zur rna-gesteuerten transkriptionsmodulation
SG11201407336PA (en)	2012-05-25	2015-03-30	Janssen Sciences Ireland Uc	Uracyl spirooxetane nucleosides
US9828602B2 (en)	2012-06-01	2017-11-28	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
WO2013181666A2 (en)	2012-06-01	2013-12-05	Isis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with fibronectin
ES2809199T3 (es)	2012-06-25	2021-03-03	Ionis Pharmaceuticals Inc	Modulación de la expresión de UBE3A-ATS
US9695416B2 (en)	2012-07-18	2017-07-04	Siemens Healthcare Diagnostics Inc.	Method of normalizing biological samples
EP3693460A1 (de)	2012-07-27	2020-08-12	Ionis Pharmaceuticals, Inc.	Modulation von mit dem reninangiotensinsystem (ras) assoziierten erkrankungen durch angiotensinogen
EP2885312B1 (de)	2012-08-15	2025-09-03	Ionis Pharmaceuticals, Inc.	Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kappungsprotokollen
EP2890704B1 (de)	2012-08-31	2018-02-28	Novartis AG	2'-ethynylnukleosidderivate zur behandlung von virusinfektionen
CA2884245C (en)	2012-09-06	2023-03-14	The University Of Chicago	Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
WO2014045126A2 (en)	2012-09-18	2014-03-27	Uti Limited Partnership	Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014059353A2 (en)	2012-10-11	2014-04-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US9523094B2 (en)	2012-10-11	2016-12-20	Ionis Pharmaceuticals, Inc.	Methods of treating kennedy's disease
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
EP3459549B1 (de)	2012-10-12	2022-04-06	Ionis Pharmaceuticals, Inc.	Selektive antisense-verbindungen und verwendungen davon
HK1212597A1 (zh)	2012-10-15	2016-06-17	Isis Pharmaceuticals, Inc.	用於調節c90rf72表達的組合物
WO2014062736A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for monitoring c9orf72 expression
ES2762326T5 (es)	2012-10-15	2023-04-27	Ionis Pharmaceuticals Inc	Métodos para modular la expresión de C9ORF72
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6542669B2 (ja)	2012-10-31	2019-07-10	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	癌の治療
BR112015010220A2 (pt)	2012-11-05	2017-12-05	Pronai Therapeutics Inc	métodos de utilização de biomarcadores para tratamento de câncer
US10201556B2 (en)	2012-11-06	2019-02-12	Interna Technologies B.V.	Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
US10077443B2 (en)	2012-11-15	2018-09-18	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugates
BR112015012051A2 (pt)	2012-11-26	2017-12-12	Roche Innovation Ct Copenhagen As	composições e métodos para modulação de expressão de fgfr3
US9695475B2 (en)	2012-12-11	2017-07-04	Ionis Pharmaceuticals, Inc.	Competitive modulation of microRNAs
GEP201706757B (en)	2012-12-21	2017-10-25	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
WO2014108759A1 (en)	2013-01-14	2014-07-17	Pierfrancesco Tassone	INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
WO2014113540A1 (en)	2013-01-16	2014-07-24	Iowa State University Research Foundation, Inc.	A deep intronic target for splicing correction on spinal muscular atrophy gene
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
CN104955952A (zh)	2013-01-30	2015-09-30	弗·哈夫曼-拉罗切有限公司	Lna寡核苷酸碳水化合物缀合物
WO2014120861A2 (en)	2013-01-31	2014-08-07	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
AU2014216137B2 (en)	2013-02-14	2018-05-10	Ionis Pharmaceuticals, Inc.	Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
AU2014200958B2 (en)	2013-02-25	2016-01-14	Seegene, Inc.	Detection of nucleotide variation on target nucleic acid sequence
US10086093B2 (en)	2013-02-28	2018-10-02	The General Hospital Corporation	miRNA profiling compositions and methods of use
CN105143470B (zh)	2013-02-28	2020-06-09	德克萨斯大学系统董事会	用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
CA2901983A1 (en)	2013-03-01	2014-09-04	National University Corporation Tokyo Medical And Dental University	Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
EP2971115B1 (de)	2013-03-13	2022-07-27	Seegene, Inc.	Quantifizierung von zielnukleinsäuren unter verwendung von schmelzspitzenwertanalyse
DK2971098T3 (en)	2013-03-14	2019-02-18	Translate Bio Inc	QUANTITATIVE ASSESSMENT FOR CAPE EFFECTIVENESS OF MESSENGER RNA
CN105051213A (zh)	2013-03-14	2015-11-11	夏尔人类遗传性治疗公司	信使rna加帽效率的定量评估
ES2807379T3 (es)	2013-03-14	2021-02-22	Ionis Pharmaceuticals Inc	Composiciones y métodos para regular la expresión de Tau
US9273349B2 (en)	2013-03-14	2016-03-01	Affymetrix, Inc.	Detection of nucleic acids
WO2014143637A1 (en)	2013-03-15	2014-09-18	The Board Of Trustees Of The University Of Illinois	Methods and compositions for enhancing immunoassays
WO2014172698A1 (en)	2013-04-19	2014-10-23	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
WO2014179335A1 (en)	2013-04-29	2014-11-06	Memorial Sloan Kettering Cancer Center	Compositions and methods for altering second messenger signaling
DK2991656T3 (da)	2013-05-01	2020-03-23	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
ES2700277T3 (es)	2013-05-30	2019-02-14	Univ Nat Corp Tokyo Medical & Dental	Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos
EP3007704B1 (de)	2013-06-13	2021-01-06	Antisense Therapeutics Ltd	Kombinationstherapie der akromegalie
CN105324119A (zh)	2013-06-16	2016-02-10	国立大学法人东京医科齿科大学	具有外显子跳跃效应的双链反义核酸
WO2014205449A2 (en)	2013-06-21	2014-12-24	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
ES2770667T3 (es)	2013-06-27	2020-07-02	Roche Innovation Ct Copenhagen As	Oligómeros antisentido y conjugados que se dirigen a PCSK9
EP3017044B1 (de)	2013-07-02	2020-02-26	Ionis Pharmaceuticals, Inc.	Modulatoren des wachstumshormonrezeptors
EP3022176B8 (de)	2013-07-15	2019-12-25	The Regents of the University of California	Eingeschränkte azacyclische analoga von fty720
EP3022319B1 (de)	2013-07-15	2023-05-17	Seegene, Inc.	Erkennung einer nukleinsäurezielsequenz durch pto-spaltung und erweiterungsabhängige immobilisierte oligonukleotidhybridisierung
TWI772856B (zh)	2013-07-19	2022-08-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
DK3041854T3 (da)	2013-08-08	2020-03-02	Scripps Research Inst	En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
TW201536329A (zh)	2013-08-09	2015-10-01	Isis Pharmaceuticals Inc	用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
KR102365486B1 (ko)	2013-08-28	2022-02-18	아이오니스 파마수티컬즈, 인코포레이티드	프리칼리크레인 (pkk) 발현의 조절
DK3043827T3 (da)	2013-09-13	2019-08-26	Ionis Pharmaceuticals Inc	Modulatorer af komplement faktor b
US10077444B2 (en)	2013-10-02	2018-09-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
TWI768330B (zh)	2013-10-04	2022-06-21	美國西奈山伊坎醫學院	抑制alas1基因表現的組合物及方法
EP4166667A3 (de)	2013-10-11	2023-08-02	Ionis Pharmaceuticals, Inc.	Zusammensetzungen zur modulierung der c9orf72-expression
US10159652B2 (en)	2013-10-16	2018-12-25	The University Of British Columbia	Device for formulating particles at small volumes
US11447814B2 (en)	2013-10-18	2022-09-20	Seegene, Inc.	Detection of target nucleic acid sequence on solid phase by PTO cleavage and extension using HCTO assay
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
EP3760719A1 (de)	2013-11-18	2021-01-06	CRISPR Therapeutics AG	Crispr-cas-systemmaterialien und verfahren
WO2015075166A1 (en)	2013-11-22	2015-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of a bacterial infection
JP6527516B2 (ja)	2013-12-03	2019-06-05	ノースウェスタンユニバーシティ	リポソーム粒子、前述のものを作製する方法及びその使用
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
US9994831B2 (en)	2013-12-12	2018-06-12	The Regents Of The University Of California	Methods and compositions for modifying a single stranded target nucleic acid
SG10201804960RA (en)	2013-12-12	2018-07-30	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
CN111394355A (zh)	2013-12-24	2020-07-10	Ionis制药公司	促血管生成素样3表达的调节
US9765332B2 (en)	2014-01-29	2017-09-19	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
AU2015217301A1 (en)	2014-02-11	2016-08-25	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) iRNA compositions and methods of use thereof
EP2907874A1 (de)	2014-02-14	2015-08-19	Université de Lausanne	MiR-21-3p-Inhibitoren bei Hauterkrankungen
EP3119789B1 (de)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
CN106103717A (zh)	2014-03-19	2016-11-09	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
RS60707B1 (sr)	2014-04-01	2020-09-30	Biogen Ma Inc	Kompozicije za modulaciju ekspresije sod-1
US10513706B2 (en)	2014-04-09	2019-12-24	The Scripps Research Institute	Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
DK3137476T3 (da)	2014-04-28	2019-11-18	Ionis Pharmaceuticals Inc	Linker-modificerede oligomerforbindelser
PT3137605T (pt)	2014-05-01	2020-12-18	Ionis Pharmaceuticals Inc	Composições e métodos para modulação da expressão de angiopoietina de tipo 3
US10098959B2 (en)	2014-05-01	2018-10-16	Ionis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
SG11201608502TA (en)	2014-05-01	2016-11-29	Ionis Pharmaceuticals Inc	Compositions and methods for modulating complement factor b expression
CN110903337A (zh)	2014-05-01	2020-03-24	Ionis制药公司	用于调节生长激素受体表达的组合物和方法
EP3862362A3 (de)	2014-05-01	2021-10-27	Ionis Pharmaceuticals, Inc.	Konjugate con antisens-oligonukleotides und deren verwendung zur modulation der pkk-expression
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
GB201408623D0 (en)	2014-05-15	2014-07-02	Santaris Pharma As	Oligomers and oligomer conjugates
CA3215908A1 (en)	2014-05-22	2015-11-26	Alnylam Pharmaceuticals, Inc.	Angiotensinogen (agt) irna compositions and methods of use thereof
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP4039807A1 (de)	2014-06-10	2022-08-10	Erasmus University Rotterdam Medical Center	Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
JP6562517B2 (ja) *	2014-07-31	2019-08-21	国立大学法人大阪大学	架橋型ヌクレオシドおよびヌクレオチド
WO2016028940A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
IL234246A0 (en)	2014-08-21	2014-11-30	Omrix Biopharmaceuticals Ltd	Stabilized thrombin
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016034611A1 (en)	2014-09-02	2016-03-10	Max-Delbrück-Centrum für Molekulare Medizin	Antisense oligonucleotides targeting 3'utr region of a20
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
BR112017004056A2 (pt)	2014-09-12	2017-12-05	Biogen Ma Inc	composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
WO2016041058A1 (en)	2014-09-18	2016-03-24	The University Of British Columbia	Allele-specific therapy for huntington disease haplotypes
AU2015323973A1 (en)	2014-09-29	2017-04-20	The Jackson Laboratory	High efficiency, high throughput generation of genetically modified mammals by electroporation
CN107109411B (zh)	2014-10-03	2022-07-01	冷泉港实验室	核基因输出的定向增加
WO2016061131A1 (en)	2014-10-14	2016-04-21	The J. David Gladstone Institutes	Compositions and methods for reactivating latent immunodeficiency virus
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (de)	2014-10-30	2021-04-07	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
TWI710633B (zh)	2014-11-10	2020-11-21	美商阿尼拉製藥公司	Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
US20170312297A1 (en)	2014-11-10	2017-11-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Long Acting Pharmaceutical Compositions For Hepatitis C
PE20170922A1 (es)	2014-11-10	2017-07-12	Glaxosmithkline Intellectual Property (No 2) Ltd	Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
HK1244843A1 (zh)	2014-11-17	2018-08-17	Alnylam Pharmaceuticals, Inc.	载脂蛋白c3(apoc3)irna组合物及其使用方法
KR20170078843A (ko)	2014-11-21	2017-07-07	노오쓰웨스턴 유니버시티	구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수
WO2016086104A1 (en)	2014-11-25	2016-06-02	Ionis Pharmaceuticals, Inc.	Modulation of ube3a-ats expression
CA2970795A1 (en)	2014-12-18	2016-06-23	Alnylam Pharmaceuticals, Inc.	Reversir compounds
CA2970966A1 (en)	2014-12-22	2016-06-30	Anapa Biotech A/S	Dual quenching assay for multiplex detection of target nucleic acids
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
CA2975875A1 (en)	2015-02-04	2016-08-11	Genentech, Inc.	Mutant smoothened and methods of using the same
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016130943A1 (en)	2015-02-13	2016-08-18	Rana Therapeutics, Inc.	Hybrid oligonucleotides and uses thereof
JP6764870B2 (ja)	2015-02-24	2020-10-07	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	連続フローマイクロ流体システム
BR112017017178A2 (pt)	2015-02-26	2018-04-03	Ionis Pharmaceuticals Inc	moduladores específicos de alelo de rodopsina de p23h
WO2016141236A1 (en)	2015-03-03	2016-09-09	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
DK3265564T3 (da)	2015-03-03	2022-04-11	Ionis Pharmaceuticals Inc	Fremgangsmåde til modulering af mecp2-ekspression
MX2017012426A (es)	2015-04-03	2018-01-26	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion de tmprss6.
TN2017000427A1 (en)	2015-04-08	2019-04-12	Univ Northwestern	Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EA201792263A1 (ru)	2015-04-13	2018-08-31	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RS60230B1 (sr)	2015-04-16	2020-06-30	Ionis Pharmaceuticals Inc	Kompozicije za moduliranje ekspresije c9orf72
EP3303634B1 (de)	2015-06-03	2023-08-30	The Regents of The University of California	Cas9-varianten und verfahren zur verwendung davon
EP4365291A3 (de)	2015-06-12	2024-08-14	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c5-irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
EP3919619A1 (de)	2015-07-17	2021-12-08	Alnylam Pharmaceuticals, Inc.	Mehrfach gerichtete einheitlichen konjugate
EP3331536A4 (de)	2015-08-03	2019-03-27	The Regents of The University of California	Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
JP6835826B2 (ja)	2015-08-24	2021-02-24	ロシュイノベーションセンターコペンハーゲンエーエス	Ｌｎａ−ｇプロセス
KR20250145703A (ko)	2015-09-02	2025-10-13	알닐람 파마슈티칼스 인코포레이티드	프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
WO2017045689A1 (en)	2015-09-14	2017-03-23	Pentabase Aps	Methods and materials for detection of mutations
TW201718857A (zh)	2015-09-14	2017-06-01	艾爾妮蘭製藥公司	用於抑制alas1基因表現之組合物及方法
EP3350328A1 (de)	2015-09-14	2018-07-25	Alnylam Pharmaceuticals, Inc.	Gegen patatin-like-phospholipasedomäne gerichtete polynukleotidmittel mit 3 (pnpla3) und verfahren zur verwendung davon
TW201718618A (zh) *	2015-09-18	2017-06-01	田邊三菱製藥股份有限公司	架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
US20190048340A1 (en)	2015-09-24	2019-02-14	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP3352753A4 (de)	2015-09-24	2019-03-13	The Regents of The University of California	Synthetische sphingolipid-ähnliche moleküle, arzneimittel, verfahren zu deren synthese und behandlungsverfahren
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
CN113817735A (zh)	2015-10-08	2021-12-21	Ionis制药公司	用于调节血管紧张素原表达的化合物和方法
EP3359685B1 (de)	2015-10-09	2026-01-28	University Of Southampton	Modulation der genexpression für deregulierte proteinexpression
WO2017066782A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Hydrophobic mrna cap analogs
WO2017066791A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Sugar substituted mrna cap analogs
WO2017066789A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs with modified sugar
WO2017066781A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs with modified phosphate linkage
JP2018530587A (ja)	2015-10-16	2018-10-18	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
EP3183347A4 (de)	2015-10-17	2018-04-18	Lifesplice Pharma LLC	Spleissmodulierende oligonukleotide und verfahren zur verwendung davon
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
EP3368089B1 (de)	2015-10-26	2025-11-05	Translate Bio Ma, Inc.	Nanopartikelformulierungen zur freisetzung von nukleinsäurekomplexen
JP7023842B2 (ja)	2015-10-29	2022-02-22	テンプルユニヴァーシティ－オブザコモンウェルスシステムオブハイアーエデュケーション	Ｄｎａポリメラーゼシータによる核酸の３’末端の修飾
US11260073B2 (en)	2015-11-02	2022-03-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating C90RF72
US20190046555A1 (en)	2015-11-06	2019-02-14	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds for use in therapy
AU2016349625B2 (en)	2015-11-06	2022-07-07	Ionis Pharmaceuticals, Inc.	Modulating apolipoprotein (a) expression
HUE067905T2 (hu)	2015-11-12	2024-11-28	Hoffmann La Roche	Oligonukleotidok paternális UBE3A expresszió indukálására
JP2019500899A (ja)	2015-11-23	2019-01-17	ザリージェンツオブザユニバーシティオブカリフォルニア	ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作
FI3386518T3 (fi)	2015-12-07	2025-09-25	Genzyme Corp	Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
CA3007152A1 (en)	2015-12-07	2017-06-15	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017098468A1 (en)	2015-12-09	2017-06-15	Novartis Ag	Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
WO2017100542A1 (en)	2015-12-10	2017-06-15	Alnylam Pharmaceuticals, Inc.	Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
EP3933041B1 (de)	2015-12-14	2024-01-31	Cold Spring Harbor Laboratory	Antisense-oligomere zur behandlung von autosomaldominierender geistiger behinderung
PH12018501207B1 (en)	2015-12-21	2024-02-23	Novartis Ag	Compositions and methods for decreasing tau expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
AU2016385135B2 (en)	2016-01-06	2022-02-17	The University Of British Columbia	Bifurcating mixers and methods of their use and manufacture
KR20180097756A (ko)	2016-01-15	2018-08-31	더 잭슨 래보라토리	Ｃａｓ9 단백질의 다중-주기 전기천공법에 의한 유전자 조작된 비-사람 포유동물
JP2019509721A (ja)	2016-02-04	2019-04-11	キュリス，インコーポレイテッド	突然変異体スムースンド及びその使用方法
WO2017142054A1 (ja)	2016-02-17	2017-08-24	国立大学法人東京工業大学	人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
EP4354140A3 (de)	2016-02-26	2024-07-24	The Board of Trustees of the Leland Stanford Junior University	Multiplexierte einzelmolekül-rna-visualisierung mit einem zwei-sonden-proximitätsligationssystem
AU2017229778A1 (en)	2016-03-09	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods and compositions for inhibiting PMP22 expression
KR20250065735A (ko)	2016-03-14	2025-05-13	에프. 호프만-라 로슈 아게	Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
AU2017234678A1 (en)	2016-03-16	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
AU2017248637A1 (en)	2016-04-13	2018-09-27	Ionis Pharmaceuticals, Inc.	Methods for reducing C9ORF72 expression
EP3442983A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Trityl-mono-galnac-verbindungen und deren verwendung
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
SG10201913477UA (en)	2016-04-29	2020-02-27	Univ Nanyang Tech	G-quadruplex-containing antisense oligonucleotides
JP7091255B2 (ja)	2016-05-06	2022-06-27	アイオニス・ファーマシューティカルズ・インコーポレイテッド	Ｇｌｐ－１受容体リガンド部分コンジュゲート化オリゴヌクレオチドおよびその使用
WO2017214112A1 (en)	2016-06-06	2017-12-14	Arrowhead Pharmaceuticals, Inc.	5'-cyclo-phosphonate modified nucleotides
EP3469083A1 (de)	2016-06-10	2019-04-17	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
CA3027953A1 (en)	2016-06-15	2017-12-21	Streck, Inc.	Assays and methods for determining microbial resistance
US10337051B2 (en)	2016-06-16	2019-07-02	The Regents Of The University Of California	Methods and compositions for detecting a target RNA
CN109414448B (zh)	2016-06-17	2021-10-26	豪夫迈·罗氏有限公司	用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
HUE060123T2 (hu)	2016-06-24	2023-01-28	Scripps Research Inst	Új nukleozid-trifoszfát-transzporter és alkalmazásai
AU2017289204A1 (en)	2016-07-01	2019-01-17	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating HTRA1 expression
ES2935658T3 (es)	2016-07-15	2023-03-09	Ionis Pharmaceuticals Inc	Compuestos y métodos para la modulación de SMN2
WO2018024849A1 (en)	2016-08-03	2018-02-08	Aalborg Universitet	ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
SG10201607303YA (en)	2016-09-01	2018-04-27	Agency Science Tech & Res	Antisense oligonucleotides to induce exon skipping
KR102350647B1 (ko) *	2016-09-02	2022-01-14	다이서나 파마수이티컬, 인크.	4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
ES2963428T3 (es)	2016-09-29	2024-03-27	Biogen Ma Inc	Compuestos y métodos para reducir la expresión de Tau
EP3522898A4 (de)	2016-10-06	2020-05-27	Ionis Pharmaceuticals, Inc.	Verfahren zum konjugieren von oligomeren verbindungen
US10487105B2 (en)	2016-10-19	2019-11-26	Arcturus Therapeutics, Inc.	Trinucleotide MRNA cap analogs
SG10201609048RA (en)	2016-10-28	2018-05-30	Agency Science Tech & Res	Antisense oligonucleotides
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
US20190284621A1 (en)	2016-11-11	2019-09-19	Roche Innovation Center Copenhagen A/S	Therapeutic oligonucleotides capture and detection
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
US11371090B2 (en)	2016-12-12	2022-06-28	Dana-Farber Cancer Institute, Inc.	Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
CN110199023A (zh)	2016-12-28	2019-09-03	第一三共株式会社	阿尔波特氏综合症治疗药
BR112019014282A2 (pt)	2017-01-10	2020-03-03	Arrowhead Pharmaceuticals, Inc.	Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
US20200216845A1 (en)	2017-01-13	2020-07-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rela expression
WO2018130585A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating relb expression
WO2018130582A1 (en)	2017-01-13	2018-07-19	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating rel expression
US20190345495A1 (en)	2017-01-13	2019-11-14	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb2 expression
US20190367920A1 (en)	2017-01-13	2019-12-05	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides for modulating nfkb1 expression
CN110337495B (zh)	2017-02-06	2024-03-29	日产化学株式会社	单链寡核苷酸
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
US11963974B2 (en)	2017-03-10	2024-04-23	National Center For Child Health And Development	Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
JOP20190215A1 (ar)	2017-03-24	2019-09-19	Ionis Pharmaceuticals Inc	مُعدّلات التعبير الوراثي عن pcsk9
WO2018181428A1 (ja)	2017-03-29	2018-10-04	塩野義製薬株式会社	核酸医薬及び多分岐脂質の複合体
IL269927B2 (en)	2017-04-18	2025-04-01	Alnylam Pharmaceuticals Inc	Methods of treating patients with hepatitis B virus infection
EP3622062A4 (de)	2017-05-10	2020-10-14	The Regents of the University of California	Gerichtetes editing von zellulärer rna durch nukleare abgabe von crispr/cas9
US20190055564A1 (en)	2017-06-01	2019-02-21	F. Hoffmann-La Roche Ag	Antisense oligonucleotides for modulating htra1 expression
WO2018226788A1 (en)	2017-06-07	2018-12-13	University Of Massachusetts	Anti-adam33 oligonucleotides and related methods
UY37803A (es)	2017-07-10	2019-02-28	Genzyme Corp	Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
MA49716A (fr)	2017-07-11	2021-04-07	Scripps Research Inst	Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
AU2018300069C1 (en)	2017-07-11	2025-11-20	Synthorx, Inc.	Incorporation of unnatural nucleotides and methods thereof
JP2020526558A (ja)	2017-07-13	2020-08-31	ノースウェスタンユニバーシティ	オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
WO2019023243A1 (en)	2017-07-24	2019-01-31	Dana-Farber Cancer Institute, Inc.	METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE
AU2018307294B2 (en)	2017-07-26	2025-04-17	Nissan Chemical Corporation	Single-stranded oligonucleotide
WO2019028419A1 (en)	2017-08-03	2019-02-07	Synthorx, Inc.	CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
WO2019030313A2 (en)	2017-08-11	2019-02-14	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
US11197884B2 (en)	2017-08-18	2021-12-14	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
DK3669193T3 (da) *	2017-08-18	2022-07-11	European Molecular Biology Laboratory	Forbedret rna-interaktom-registrering (eric)
WO2019038228A1 (en)	2017-08-22	2019-02-28	Roche Innovation Center Copenhagen A/S	OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
SG11202001590RA (en)	2017-08-25	2020-03-30	Stoke Therapeutics Inc	Antisense oligomers for treatment of conditions and diseases
KR102380264B1 (ko)	2017-08-31	2022-03-29	주식회사 씨젠	다이머-형성 프라이머 쌍을 이용한 구성요소의 성능 평가
US11401546B2 (en)	2017-09-29	2022-08-02	Seegene, Inc.	Detection of target nucleic acid sequences by PTO cleavage and extension-dependent extension assay
CN111226114A (zh)	2017-10-13	2020-06-02	罗氏创新中心哥本哈根有限公司	用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
UA126931C2 (uk)	2017-10-16	2023-02-22	Ф. Хоффманн-Ля Рош Аг	МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
WO2019076919A1 (en)	2017-10-17	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	COMBINED TREATMENT OF CYSTIC FIBROSIS
AU2018360697A1 (en)	2017-11-01	2020-05-14	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
US11497762B2 (en)	2017-11-03	2022-11-15	Interna Technologies B.V.	MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
WO2019111791A1 (ja) *	2017-12-07	2019-06-13	第一三共株式会社	ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
US20200385714A1 (en)	2017-12-11	2020-12-10	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en)	2017-12-12	2019-06-20	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating rb1 expression
JP2021506251A (ja)	2017-12-14	2021-02-22	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
WO2019118916A1 (en)	2017-12-14	2019-06-20	Ionis Pharmaceuticals, Inc.	Conjugated antisense compounds and their use
EP3724355A1 (de)	2017-12-15	2020-10-21	Novartis AG	Polya-schwanzlängenanalyse der rna mittels massenspektrometrie
JP2021508491A (ja)	2017-12-18	2021-03-11	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
JP2021507253A (ja)	2017-12-21	2021-02-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｈｔｒａ１ｒｎａアンタゴニストについてのコンパニオン診断
CN111448316B (zh)	2017-12-22	2025-02-14	罗氏创新中心哥本哈根有限公司	新的硫代亚磷酰胺
WO2019122279A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019122282A1 (en)	2017-12-22	2019-06-27	Roche Innovation Center Copenhagen A/S	Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
KR102776907B1 (ko)	2017-12-29	2025-03-11	더 스크립스 리서치 인스티튜트	비천연 염기쌍 조성물 및 사용 방법
US20210095274A1 (en)	2018-01-10	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating pias4 expression
EA202091693A1 (ru)	2018-01-12	2021-04-14	Бристол-Маерс Сквибб Компани	Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
US20210095275A1 (en)	2018-01-12	2021-04-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating gsk3b expression
AU2019207859A1 (en)	2018-01-12	2020-07-02	Roche Innovation Center Copenhagen A/S	Alpha-synuclein antisense oligonucleotides and uses thereof
BR112020013994A2 (pt)	2018-01-12	2020-12-08	Bristol-Myers Squibb Company	Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
BR112020014425A2 (pt)	2018-01-15	2020-12-29	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de dnm2
CN111615558A (zh)	2018-01-17	2020-09-01	罗氏创新中心哥本哈根有限公司	用于调节erc1表达的寡核苷酸
WO2019141723A1 (en)	2018-01-18	2019-07-25	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en)	2018-01-26	2019-08-01	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating csnk1d expression
CA3088071A1 (en)	2018-02-09	2019-08-15	Genentech, Inc.	Oligonucleotides for modulating tmem106b expression
AU2019218987B2 (en)	2018-02-12	2025-04-24	Ionis Pharmaceuticals, Inc.	Modified compounds and uses thereof
CA3088321A1 (en)	2018-02-12	2019-08-15	Interna Technologies B.V.	Anticancer microrna and lipid formulations thereof
KR20200140805A (ko)	2018-02-21	2020-12-16	브리스톨-마이어스 스큅 컴퍼니	Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
CA3091857A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
CN111511915A (zh)	2018-03-09	2020-08-07	第一三共株式会社	糖原病Ia型治疗药
JP7550648B2 (ja)	2018-03-19	2024-09-13	クリスパーセラピューティクスアーゲー	新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
MX2020009765A (es) *	2018-03-20	2021-01-08	Tokyo Inst Tech	Oligonucleotido antisentido reducido en toxicidad.
MA52661A (fr)	2018-04-05	2021-02-17	Centre Leon Berard	Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
EP3553182A1 (de)	2018-04-11	2019-10-16	Université de Bourgogne	Verfahren zum nachweis von somatischen genetischen anomalien, kombination von fangsonden und nachweiskit
US12263205B2 (en)	2018-04-30	2025-04-01	The Children's Hospital Of Philadelphia	Methods of improving anemias by combining agents
US12060558B2 (en)	2018-05-04	2024-08-13	Stoke Therapeutics, Inc.	Methods and compositions for treatment of cholesteryl ester storage disease
WO2019217459A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
WO2019215066A1 (en)	2018-05-07	2019-11-14	Roche Innovation Center Copenhagen A/S	Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
US20210371860A1 (en)	2018-05-08	2021-12-02	Roche Innovation Center Copenhagen A/S	Oligonucleotides for modulating myh7 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
EP3793685A1 (de)	2018-05-18	2021-03-24	F. Hoffmann-La Roche AG	Pharmazeutische zusammensetzungen zur behandlung von krankheiten im zusammenhang mit mikro-rna
WO2019224172A1 (en)	2018-05-25	2019-11-28	Roche Innovation Center Copenhagen A/S	Novel process for making allofuranose from glucofuranose
WO2019233922A1 (en)	2018-06-05	2019-12-12	F. Hoffmann-La Roche Ag	Oligonucleotides for modulating atxn2 expression
US20210207136A1 (en)	2018-06-13	2021-07-08	Daiichi Sankyo Company, Limited	Myocardial dysfunction therapeutic agent
CA3110102A1 (en)	2018-06-20	2019-12-26	Yale University	Rig-i agonists and treatments using same
BR112020026073A2 (pt)	2018-06-21	2021-03-23	F. Hoffmann-La Roche Ag	método para fornecer um par de ligação, composição líquida, uso de uma composição e kit para realizar um imunoensaio heterogêneo
WO2020007772A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting gbp-1
WO2020007700A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting spi1
WO2020007702A1 (en)	2018-07-02	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting bcl2l11
SG11202012759XA (en)	2018-07-03	2021-01-28	Hoffmann La Roche	Oligonucleotides for modulating tau expression
WO2020007826A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mbtps1
WO2020007889A1 (en)	2018-07-05	2020-01-09	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting stat1
WO2020011653A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting kynu
WO2020011743A1 (en)	2018-07-09	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting mafb
WO2020011745A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers6
WO2020011869A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting tlr2
WO2020011744A2 (en)	2018-07-11	2020-01-16	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting cers5
EP4512407A3 (de)	2018-07-13	2025-09-24	F. Hoffmann-La Roche AG	Oligonukleotide zur modulation der stel1-expression
EP3823725A4 (de)	2018-07-17	2023-05-10	Aronora, Inc.	Verfahren zur sicheren reduzierung von thrombopoietin
BR112021000308A2 (pt)	2018-07-25	2021-04-13	Ionis Pharmaceuticals, Inc.	Compostos e métodos para redução da expressão de atxn2
US20210308170A1 (en)	2018-07-27	2021-10-07	Osaka University	Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
EP3830101B1 (de)	2018-07-31	2025-11-19	Roche Innovation Center Copenhagen A/S	Oligonukleotide mit einer phosphordithioat-internukleosid-verknüpfung
JP6544783B1 (ja)	2018-07-31	2019-07-17	学校法人岩手医科大学	がんの診断のためのプローブ／プライマーライブラリー
US20210292358A1 (en)	2018-07-31	2021-09-23	Roche Innovation Center Copenhagen A/S	Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
EP3830301B1 (de)	2018-08-01	2024-05-22	Mammoth Biosciences, Inc.	Programmierbare nuklease-zusammensetzungen und verwendungsverfahren dafür
CA3106701A1 (en)	2018-08-13	2020-02-20	Alnylam Pharmaceuticals, Inc.	Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
US11987792B2 (en)	2018-08-16	2024-05-21	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
BR112021003224A2 (pt)	2018-08-20	2021-07-20	Rogcon, Inc.	oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
US12275964B2 (en)	2018-08-22	2025-04-15	The Regents Of The University Of California	Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
WO2020038976A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting usp8
EP3841220A1 (de)	2018-08-23	2021-06-30	Roche Innovation Center Copenhagen A/S	Mikrorna-134-biomarker
WO2020038973A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting sptlc1
WO2020038971A1 (en)	2018-08-23	2020-02-27	Roche Innovation Center Copenhagen A/S	Antisense oligonucleotides targeting vcan
EP3844303A4 (de)	2018-08-27	2022-06-01	The Regents of The University of California	Reporternukleinsäuren für typ-v-crispr-vermittelte detektion
JP2021536239A (ja)	2018-08-28	2021-12-27	ロシュイノベーションセンターコペンハーゲンエーエス	スプライス調節化合物を使用したネオアンチゲン操作
EP3620519A1 (de)	2018-09-04	2020-03-11	F. Hoffmann-La Roche AG	Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
EP3846824B1 (de)	2018-09-07	2025-06-18	The General Hospital Corporation	Zusammensetzungen und verfahren zur immuncheckpoint-inhibition
EP3620520A1 (de)	2018-09-10	2020-03-11	Universidad del Pais Vasco	Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
EP3849584A4 (de)	2018-09-14	2022-06-22	Northwestern University	Programmierung von proteinpolymerisation mit dna
CA3105385A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
TWI856973B (zh)	2018-09-19	2024-10-01	美商Ionis製藥公司	Pnpla3表現之調節劑
CA3292164A1 (en)	2018-09-25	2025-11-29	Co Diagnostics Inc	Allele-specific design of cooperative primers for improved nucleic acid variant genotyping
WO2020069055A1 (en)	2018-09-28	2020-04-02	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
EP3873920A1 (de)	2018-11-01	2021-09-08	F. Hoffmann-La Roche AG	Gegen tia1 gerichtete antisense-oligonukleotide
ES3059360T3 (en)	2018-11-08	2026-03-19	Synthorx Inc	Interleukin 10 conjugates and uses thereof
CA3117730A1 (en)	2018-11-09	2020-05-14	Inari Agriculture, Inc.	Rna-guided nucleases and dna binding proteins
JP7356448B2 (ja) *	2018-11-12	2023-10-04	田辺三菱製薬株式会社	架橋型人工核酸ａｌｎａ
BR112021008967A2 (pt)	2018-11-15	2021-08-17	Ionis Pharmaceuticals, Inc.	moduladores da expressão de irf5
KR102624804B1 (ko)	2018-11-16	2024-01-12	에프. 호프만-라 로슈 아게	결합 쌍의 부재를 갖는 스트렙타비딘 코팅된 고체상
SG11202103794QA (en)	2018-11-21	2021-05-28	Ionis Pharmaceuticals Inc	Compounds and methods for reducing prion expression
EP3883941A1 (de)	2018-11-22	2021-09-29	Roche Innovation Center Copenhagen A/S	Pyridiniumsalze als aktivatoren bei der synthese von stereodefinierten oligonukleotiden
CA3121191A1 (en)	2018-11-28	2020-06-04	Crispr Therapeutics Ag	Optimized mrna encoding cas9 for use in lnps
WO2020109344A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Occular administration device for antisense oligonucleotides
WO2020109343A1 (en)	2018-11-29	2020-06-04	F. Hoffmann-La Roche Ag	Combination therapy for treatment of macular degeneration
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
US20220056455A1 (en)	2018-12-20	2022-02-24	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of kcnt1 related disorders
EP3899024A4 (de)	2018-12-21	2023-05-31	Ionis Pharmaceuticals, Inc.	Modulatoren der hsd17b13-expression
US20220042011A1 (en)	2018-12-21	2022-02-10	Hoffmann-La Roche Inc.	Antisense oligonucleotides targeting card9
EP3931313A2 (de)	2019-01-04	2022-01-05	Mammoth Biosciences, Inc.	Verbesserungen an programmierbarer nuklease und zusammensetzungen und verfahren zur nukleinsäureamplifikation und -detektion
KR20210116509A (ko)	2019-01-16	2021-09-27	젠자임 코포레이션	Serpinc1 irna 조성물 및 그의 이용 방법
DE102019000490A1 (de)	2019-01-23	2020-07-23	HAEMES Verwaltungsgesellschaft mbH	Verwendung von Oligonukleotiden für die Behandlung von Tumoren
EP3914232A1 (de)	2019-01-25	2021-12-01	F. Hoffmann-La Roche AG	Lipidvesikel zur oralen wirkstoffverabreichung
KR20260039812A (ko)	2019-02-06	2026-03-20	신톡스, 인크.	Il-2 콘쥬게이트 및 이의 사용 방법
WO2020169696A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Novel phosphoramidites
CA3130431A1 (en)	2019-02-20	2020-08-27	Roche Innovation Center Copenhagen A/S	Phosphonoacetate gapmer oligonucleotides
CN113474633A (zh)	2019-02-26	2021-10-01	罗氏创新中心哥本哈根有限公司	寡核苷酸配制方法
KR20210134003A (ko)	2019-02-27	2021-11-08	스톡 테라퓨틱스, 인크.	병태 및 질환의 치료를 위한 안티센스 올리고머
TW202540426A (zh)	2019-02-27	2025-10-16	美商Ionis製藥公司	Malat1表現之調節劑
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
WO2020178258A1 (en)	2019-03-05	2020-09-10	F. Hoffmann-La Roche Ag	Intracellular targeting of molecules
CA3130789A1 (en)	2019-03-07	2020-09-10	The Regents Of The University Of California	Crispr-cas effector polypeptides and methods of use thereof
WO2020186059A2 (en)	2019-03-12	2020-09-17	Crispr Therapeutics Ag	Novel high fidelity rna-programmable endonuclease systems and uses thereof
JP7530106B2 (ja)	2019-03-14	2024-08-07	レナセラピューティクス株式会社	Ｉｈｈ発現を調節するための核酸複合体
EP3941483A4 (de)	2019-03-21	2023-10-18	Arnay Sciences, Llc	Antisense-oligonukleotide zur allelspezifität
KR20210141554A (ko)	2019-03-21	2021-11-23	코디악 바이오사이언시즈, 인크.	세포외 소포 접합체 및 이의 용도
TW202104595A (zh)	2019-03-29	2021-02-01	日商田邊三菱製藥股份有限公司	用來調節ｄｕｘ４的表現之化合物、方法及醫藥組成物
FI3947684T3 (fi)	2019-03-29	2025-05-27	Ionis Pharmaceuticals Inc	Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi
KR20210149107A (ko)	2019-04-03	2021-12-08	브리스톨-마이어스 스큅 컴퍼니	Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
US11286485B2 (en)	2019-04-04	2022-03-29	Hoffmann-La Roche Inc.	Oligonucleotides for modulating ATXN2 expression
JP7499267B2 (ja)	2019-04-04	2024-06-13	エフ．ホフマン－ラロシュアーゲー	Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
CN113661168A (zh)	2019-04-16	2021-11-16	罗氏创新中心哥本哈根有限公司	用于制备核苷酸p(v)单体的新方法
JP7615052B2 (ja)	2019-04-25	2025-01-16	アジレント・テクノロジーズ・インク	ハイブリダイゼーション組成物ならびに組成物を調製および使用するための方法
JP7644025B2 (ja)	2019-04-30	2025-03-11	ロシュイノベーションセンターコペンハーゲンエーエス	レニウムキレート化ｍａｇ３オリゴヌクレオチドを調製するための新規の方法
CN114072501A (zh)	2019-05-06	2022-02-18	马萨诸塞大学	抗c9orf72寡核苷酸及相关方法
JP2022532652A (ja)	2019-05-17	2022-07-15	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの経口送達
WO2020243292A1 (en)	2019-05-28	2020-12-03	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing fus expression
US20250270657A1 (en)	2019-05-31	2025-08-28	Streck, Inc.	Detection of Antibiotic Resistance Genes
CA3140438A1 (en)	2019-06-05	2020-12-10	Masatora Fukuda	Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
MX2021015003A (es)	2019-06-06	2022-01-24	Arrowhead Pharmaceuticals Inc	Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
EP3980539A1 (de)	2019-06-06	2022-04-13	F. Hoffmann-La Roche AG	Gegen atxn3 gerichtete antisense-oligonukleotide
KR20220005571A (ko)	2019-06-07	2022-01-13	에프. 호프만-라 로슈 아게	전부 lna 올리고뉴클레오티드 혼성화
CN120988042A (zh)	2019-06-14	2025-11-21	斯克利普斯研究所	用于在半合成生物体中复制、转录和翻译的试剂和方法
EP3988558A4 (de)	2019-06-19	2022-09-28	Yamasa Corporation	Vernetzter nukleosidzwischenkristall und verfahren zu seiner herstellung sowie verfahren zur herstellung von vernetztem nukleosidamidit
EP3995153A4 (de)	2019-06-26	2023-11-22	KNC Laboratories Co., Ltd.	Nukleinsäurearzneimittel zur unterdrückung der produktion von myostatin-mrna
CN110204583B (zh) *	2019-07-01	2021-03-23	中国人民解放军军事科学院军事医学研究院	修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用
US20220251567A1 (en)	2019-07-10	2022-08-11	Inserm (Institut National De La Santè Et De La Recherche Médicale)	Methods for the treatment of epilepsy
BR112021024764A2 (pt)	2019-07-12	2022-04-19	Daiichi Sankyo Co Ltd	Oligonucleotídeo antissenso capaz de alterar o splicing de pré-mrna de dux4
EP3956450B1 (de)	2019-07-26	2025-08-13	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation von gfap
WO2021020412A1 (ja)	2019-07-30	2021-02-04	塩野義製薬株式会社	Ｍｕｒｆ１を標的とする核酸医薬
EP4007812A1 (de)	2019-08-01	2022-06-08	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
KR20220070433A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Stat6을 표적으로 하는 세포외 소포-aso 작제물
AU2020330133A1 (en)	2019-08-14	2022-03-17	Lonza Sales Ag	Extracellular vesicle-ASO constructs targeting CEBP/beta
EP4013876A1 (de)	2019-08-14	2022-06-22	Codiak BioSciences, Inc.	Extrazelluläre vesikel mit nlrp3-antagonist
CA3147701A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with antisense oligonucleotides targeting kras
CA3147366A1 (en)	2019-08-14	2021-02-18	Adam T. BOUTIN	Extracellular vesicles with stat3-antisense oligonucleotides
CA3145924A1 (en)	2019-08-14	2021-02-18	Yi Zhang	Extracellular vesicle linked to molecules and uses thereof
EP4013767A4 (de)	2019-08-15	2023-10-25	Ionis Pharmaceuticals, Inc.	Verbindungsmodifizierte oligomere verbindungen und ihre verwendungen
CN114555632A (zh)	2019-08-23	2022-05-27	新索思股份有限公司	Il-15缀合物及其用途
AU2020343255A1 (en)	2019-09-03	2022-03-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
MX2022002740A (es)	2019-09-10	2022-03-25	Synthorx Inc	Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
WO2021049504A1 (ja)	2019-09-10	2021-03-18	第一三共株式会社	肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
US12319711B2 (en)	2019-09-20	2025-06-03	Northwestern University	Spherical nucleic acids with tailored and active protein coronae
EP4034247A1 (de)	2019-09-25	2022-08-03	Codiak BioSciences, Inc.	Sting-agonisten mit exosomen zur behandlung von neuroimmunologischen erkrankungen
IT201900017234A1 (it)	2019-09-25	2021-03-25	Int Centre For Genetic Engineering And Biotechnology	Anti-miRNA per il trattamento del leiomioma
CN110590886B (zh) *	2019-09-26	2021-03-23	中国人民解放军军事科学院军事医学研究院	修饰核苷、核苷酸和核酸聚合物及其制备方法与应用
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
EP4045062A1 (de)	2019-10-14	2022-08-24	Astrazeneca AB	Modulatoren der pnpla3-expression
WO2021074657A1 (en)	2019-10-17	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination treatment for cystic fibrosis
WO2021076828A1 (en)	2019-10-18	2021-04-22	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
IL292286A (en) *	2019-10-18	2022-06-01	Daiichi Sankyo Co Ltd	Production method for bicyclic phosphoramidite
TW202134435A (zh)	2019-10-22	2021-09-16	美商阿尼拉製藥公司	補體成分ｃ３ｉｒｎａ組成物及其使用方法
EP4052730A4 (de) *	2019-10-28	2023-06-14	National University Corporation Tokai National Higher Education and Research System	Nukleosidderivat und verwendung davon
US12378560B2 (en)	2019-10-29	2025-08-05	Northwestern University	Sequence multiplicity within spherical nucleic acids
CN119499394A (zh)	2019-11-01	2025-02-25	阿尔尼拉姆医药品有限公司	亨廷顿（HTT）iRNA药剂组合物及其使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4055165A1 (de)	2019-11-06	2022-09-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
CA3160329A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
KR20220115946A (ko)	2019-11-13	2022-08-19	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
US20230016983A1 (en)	2019-11-19	2023-01-19	lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)	Antisense oligonucleotides and thier use for the treatment of cancer
WO2021102373A1 (en)	2019-11-22	2021-05-27	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
EP4065711A1 (de)	2019-11-27	2022-10-05	CRISPR Therapeutics AG	Verfahren zur synthese von rna-molekülen
WO2021113773A2 (en)	2019-12-04	2021-06-10	Pai Athma A	Identifying non-productive splice sites
MX2022006950A (es)	2019-12-11	2022-11-07	Intellia Therapeutics Inc	Arn guía modificados para edición de genes.
EP4073251A1 (de)	2019-12-13	2022-10-19	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
KR20220111315A (ko)	2019-12-18	2022-08-09	에프. 호프만-라 로슈 아게	연속 표지화 방식을 사용하는 합성에 의한 시퀀싱 방법
US20230020092A1 (en)	2019-12-19	2023-01-19	Entrada Therapeutics, Inc.	Compositions for delivery of antisense compounds
JP2023506954A (ja)	2019-12-19	2023-02-20	エフ．ホフマン－ラロシュエージー．	Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
JP2023506550A (ja)	2019-12-19	2023-02-16	エフ．ホフマン－ラロシュエージー．	Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
CN114829599A (zh)	2019-12-19	2022-07-29	豪夫迈·罗氏有限公司	Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
CN115516091A (zh)	2019-12-19	2022-12-23	豪夫迈·罗氏有限公司	Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
CN114901821A (zh)	2019-12-19	2022-08-12	豪夫迈·罗氏有限公司	Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
EP4077672A1 (de)	2019-12-20	2022-10-26	F. Hoffmann-La Roche AG	Verbesserte oligonukleotide zur hemmung der scn9a-expression
CN114828852A (zh)	2019-12-24	2022-07-29	豪夫迈·罗氏有限公司	用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
EP4081639A1 (de)	2019-12-24	2022-11-02	F. Hoffmann-La Roche AG	Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
EP4098747A4 (de)	2020-01-31	2025-03-26	Sanwa Kagaku Kenkyusho Co., Ltd.	Antisense-oligonukleotid von atn1
WO2021158810A1 (en)	2020-02-05	2021-08-12	Bristol-Myers Squibb Company	Oligonucleotides for splice modulation of camk2d
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
US12312585B2 (en)	2020-02-14	2025-05-27	University Of Massachusetts	Oligonucleotides targeting frataxin and related methods
KR20220143106A (ko)	2020-02-18	2022-10-24	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
AU2021224588B2 (en)	2020-02-18	2024-07-18	Gilead Sciences, Inc.	Antiviral compounds
TWI794742B (zh)	2020-02-18	2023-03-01	美商基利科學股份有限公司	抗病毒化合物
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
CR20220485A (es)	2020-02-28	2022-11-10	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular smn2
EP4110916A1 (de)	2020-02-28	2023-01-04	F. Hoffmann-La Roche AG	Oligonukleotide zum modulieren von cd73-exon-7-spleissen
JPWO2021177418A1 (de)	2020-03-04	2021-09-10
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022017822A2 (pt)	2020-03-06	2022-11-08	Alnylam Pharmaceuticals Inc	Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
KR20220152270A (ko)	2020-03-06	2022-11-15	알닐람 파마슈티칼스 인코포레이티드	트랜스티레틴 (ttr)의 발현을 억제하기 위한 조성물 및 방법
EP4119167A4 (de)	2020-03-11	2025-08-06	Biocomber Co Ltd	Einsträngiges nukleinsäuremolekül zur induzierung von 1-rahmenverschiebung und zusammensetzung
WO2021184020A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Methods of treating neuroinflammation
WO2021184021A1 (en)	2020-03-13	2021-09-16	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting pmp22
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CN115843299A (zh)	2020-03-31	2023-03-24	詹森生物制药有限公司	寡核苷酸的合成和相关化合物
WO2021202902A1 (en)	2020-04-01	2021-10-07	Alnylam Pharmaceuticals, Inc.	ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4133078A1 (de)	2020-04-06	2023-02-15	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der myoc-expression
EP4133076A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
CA3179678A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
AU2021260934A1 (en)	2020-04-21	2022-11-24	Flagship Pioneering, Inc.	Bifunctional molecules and methods of using thereof
KR20230018377A (ko)	2020-04-27	2023-02-07	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
MX2022013606A (es)	2020-04-30	2023-01-16	Alnylam Pharmaceuticals Inc	Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
WO2021231204A1 (en)	2020-05-11	2021-11-18	Genentech, Inc.	Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
BR112022022889A2 (pt)	2020-05-11	2023-04-04	Stoke Therapeutics Inc	Oligômeros antissentido de opa1 para tratamento de condições e doenças
JP2023527693A (ja)	2020-05-11	2023-06-30	ジェネンテック，インコーポレイテッド	神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
CN115551519A (zh)	2020-05-11	2022-12-30	基因泰克公司	用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
JP7776420B2 (ja)	2020-05-12	2025-11-26	田辺三菱製薬株式会社	Ａｔａｘｉｎ３発現を調節するための化合物、方法及び医薬組成物
TW202208628A (zh)	2020-05-13	2022-03-01	瑞士商赫孚孟拉羅股份公司	靶向顆粒蛋白前體之寡核苷酸促效劑
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231692A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021237097A1 (en)	2020-05-21	2021-11-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
CN115884777A (zh)	2020-05-22	2023-03-31	豪夫迈·罗氏有限公司	用于card9的剪接调节的寡核苷酸
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
US20230212572A1 (en)	2020-06-09	2023-07-06	Roche Innovation Center Copenhagen A/S	Guanosine Analogues for Use in Therapeutics Polynucleotides
CN116075592A (zh)	2020-06-09	2023-05-05	阿尔尼拉姆医药品有限公司	用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
TW202214856A (zh)	2020-06-18	2022-04-16	美商阿尼拉製藥公司	黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
AR122731A1 (es)	2020-06-26	2022-10-05	Hoffmann La Roche	Oligonucleótidos mejorados para modular la expresión de fubp1
CN111732623B (zh) *	2020-06-30	2022-01-18	中国科学院化学研究所	一种三异丙基硅乙炔修饰的脱氧胞苷亚磷酰胺单体及其制备方法与应用
KR20230034333A (ko)	2020-07-02	2023-03-09	라이프 테크놀로지스 코포레이션	트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
EP4179079A1 (de)	2020-07-10	2023-05-17	Horizon Discovery Limited	Verfahren zur herstellung genetisch modifizierter zellen
KR20230050336A (ko)	2020-07-10	2023-04-14	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)	뇌전증을 치료하기 위한 방법과 조성물
WO2022018155A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Lna oligonucleotides for splice modulation of stmn2
WO2022018187A1 (en)	2020-07-23	2022-01-27	F. Hoffmann-La Roche Ag	Oligonucleotides targeting rna binding protein sites
JP7722666B2 (ja)	2020-07-28	2025-08-13	神戸天然物化学株式会社	アンギオテンシン変換酵素２遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
JP2023538630A (ja)	2020-08-21	2023-09-08	エフ．ホフマン－ラロシュアーゲー	Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
JP7483127B2 (ja)	2020-08-31	2024-05-14	シージーンアイエヌシー	オリゴヌクレオチドのデザイン用核酸配列データセットを提供するためのコンピュータ具現方法
TW202227102A (zh)	2020-09-22	2022-07-16	瑞典商阿斯特捷利康公司	治療脂肪肝病之方法
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2023544413A (ja)	2020-10-05	2023-10-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	Ｇタンパク質共役受容体７５（ＧＰＲ７５）ｉＲＮＡ組成物およびその使用方法
WO2022076596A1 (en)	2020-10-06	2022-04-14	Codiak Biosciences, Inc.	Extracellular vesicle-aso constructs targeting stat6
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4252846A4 (de)	2020-11-06	2025-12-03	Sumitomo Pharma Co Ltd	Regulator zur expression und/oder funktion des rps25-gens
KR20230107625A (ko)	2020-11-13	2023-07-17	알닐람 파마슈티칼스 인코포레이티드	응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
KR20230110293A (ko)	2020-11-18	2023-07-21	렘바 비브이	Umlilo 안티센스 전사 억제제
EP4136092B1 (de)	2020-11-18	2024-07-31	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der angiotensinogenexpression
WO2022106695A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
TW202237842A (zh)	2020-12-03	2022-10-01	瑞士商赫孚孟拉羅股份公司	靶向ａｔｘｎ３之反義寡核苷酸
WO2022117747A2 (en)	2020-12-03	2022-06-09	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting atxn3
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
EP4261284A4 (de)	2020-12-08	2025-07-16	Univ Fukuoka	Stabile zieleditierende guide-rna mit darin eingeführter chemisch modifizierter nukleinsäure
JP2023553069A (ja)	2020-12-08	2023-12-20	エフ．ホフマン－ラロシュアーゲー	ホスホロジチオエートオリゴヌクレオチドの新規合成
GB2603454A (en)	2020-12-09	2022-08-10	Ucl Business Ltd	Novel therapeutics for the treatment of neurodegenerative disorders
CR20230308A (es)	2020-12-11	2023-09-08	Civi Biopharma Inc	Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
WO2022124410A1 (ja) *	2020-12-11	2022-06-16	ヤマサ醤油株式会社	シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法
TW202229553A (zh)	2020-12-18	2022-08-01	瑞士商赫孚孟拉羅股份公司	靶向顆粒蛋白前體之反義寡核苷酸
JP2023554346A (ja)	2020-12-18	2023-12-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	第ｘｉｉ因子を調節するための化合物及び方法
WO2022136140A1 (en)	2020-12-22	2022-06-30	F. Hoffmann-La Roche Ag	Oligonucleotides targeting xbp1
EP4271695A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
WO2022147214A2 (en)	2020-12-31	2022-07-07	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4274896A1 (de)	2021-01-05	2023-11-15	Alnylam Pharmaceuticals, Inc.	Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202246500A (zh)	2021-02-02	2022-12-01	瑞士商赫孚孟拉羅股份公司	用於抑制ｒｔｅｌ１表現之增強型寡核苷酸
IL304956A (en)	2021-02-12	2023-10-01	Merand Pharmaceuticals Inc	Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
WO2022174000A2 (en)	2021-02-12	2022-08-18	Alnylam Pharmaceuticals, Inc.	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
JP2024512236A (ja)	2021-02-17	2024-03-19	ロンザセールスアーゲー	細胞外ベシクル－ｎｌｒｐ３アンタゴニスト
JP2024506711A (ja)	2021-02-17	2024-02-14	ロンザセールスアーゲー	最適化リンカー及びアンカー部分を介して生物学的に活性な分子に連結した細胞外ベシクル
CN117222739A (zh)	2021-02-25	2023-12-12	阿尔尼拉姆医药品有限公司	朊病毒蛋白(prnp)irna组合物和其使用方法
US20240229036A9 (en)	2021-02-26	2024-07-11	Knc Laboratories Co., Ltd.	Nucleic acid medicine expressing splicing variant of myostatin
TW202302847A (zh)	2021-02-26	2023-01-16	美商艾拉倫製藥股份有限公司	己酮糖激酶（ＫＨＫ）ｉＲＮＡ組成物及其使用方法
IL305442A (en)	2021-03-04	2023-10-01	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
WO2022192038A1 (en)	2021-03-12	2022-09-15	Northwestern University	Antiviral vaccines using spherical nucleic acids
EP4313073A1 (de)	2021-03-26	2024-02-07	Neumirna Therapeutics ApS	Mikrorna-134-inhibitoren
US20240182889A1 (en)	2021-03-26	2024-06-06	Neumirna Therapeutics Aps	Microrna-27b inhibitors
WO2022212231A2 (en)	2021-03-29	2022-10-06	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
US20250243244A1 (en)	2021-03-31	2025-07-31	Entrada Therapeutics, Inc.	Cyclic cell penetrating peptides
IL305873A (en)	2021-04-01	2023-11-01	Lonza Sales Ag	Extracellular vesicle compositions
EP4314293A1 (de)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4323362B1 (de)	2021-04-16	2025-05-07	Gilead Sciences, Inc.	Verfahren zur herstellung von carbanukleosiden mit amiden
MX2023012586A (es)	2021-04-26	2023-10-31	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de serina 6, proteasa transmembranaria (tmprss6) y sus metodos de uso.
JP2024519293A (ja)	2021-04-29	2024-05-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	シグナル伝達兼転写活性化因子６（ＳＴＡＴ６）ｉＲＮＡ組成物およびその使用方法
US20240358845A1 (en)	2021-05-10	2024-10-31	Entrada Therapeutics, Inc.	Compositions and methods for intracellular therapeutics
WO2022240721A1 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022240760A2 (en)	2021-05-10	2022-11-17	Entrada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (de)	2021-05-20	2024-03-27	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
CA3222167A1 (en)	2021-05-31	2022-12-08	Rena Therapeutics Inc.	Ligand-binding nucleic acid complex
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
EP4347823A1 (de)	2021-06-02	2024-04-10	Alnylam Pharmaceuticals, Inc.	Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20240017865A (ko)	2021-06-04	2024-02-08	트랜슬레이트 바이오 인코포레이티드	Mrna 캡핑 효율의 정량적 평가를 위한 분석
CN117561334A (zh)	2021-06-04	2024-02-13	阿尔尼拉姆医药品有限公司	人染色体9开放阅读框72（C9ORF72）iRNA药剂组合物和其使用方法
JP2024522272A (ja)	2021-06-04	2024-06-13	ニューミルナセラピューティクスエーピーエス	アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
KR20240019228A (ko)	2021-06-08	2024-02-14	에프. 호프만-라 로슈 아게	올리고뉴클레오티드 프로그래눌린 효현제
EP4351541A2 (de)	2021-06-08	2024-04-17	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit morbus stargardt und/oder retinal-bindendem protein 4 (rbp4)
KR20240032013A (ko)	2021-06-10	2024-03-08	인텔리아 테라퓨틱스, 인크.	유전자 편집을 위한 내부 링커를 포함하는 변형된 가이드 rna
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
US20240141312A1 (en)	2021-06-11	2024-05-02	Bayer Aktiengesellschaft	Type v rna programmable endonuclease systems
IL309445A (en)	2021-06-22	2024-02-01	Acurastem Inc	PIKFYVE antisense oligonucleotides
PE20242357A1 (es)	2021-06-23	2024-12-16	Entrada Therapeutics Inc	Compuestos antisentido y metodos para dirigirse a repeticiones cug
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
IL309296A (en)	2021-06-30	2024-02-01	Alnylam Pharmaceuticals Inc	Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
WO2023283403A2 (en)	2021-07-09	2023-01-12	Alnylam Pharmaceuticals, Inc.	Bis-rnai compounds for cns delivery
KR20240025633A (ko)	2021-07-12	2024-02-27	주식회사 씨젠	용기에 수용된 용액의 높이를 결정하는 방법 및 시스템
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
CA3227115A1 (en)	2021-07-21	2023-01-26	Wen-Hsuan Chang	Unc13a antisense oligonucleotides
TW202421169A (zh)	2021-07-21	2024-06-01	美商艾拉倫製藥股份有限公司	代謝疾患相關的標靶基因ｉＲＮＡ組成物及其使用方法
CA3226878A1 (en)	2021-07-23	2023-01-26	Alnylam Pharmaceuticals, Inc.	Beta-catenin (ctnnb1) irna compositions and methods of use thereof
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
CA3227852A1 (en)	2021-08-03	2023-02-09	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna compositions and methods of use thereof
IL310295A (en)	2021-08-04	2024-03-01	Alnylam Pharmaceuticals Inc	iRNA compositions and methods for silencing angiotensinogen (AGT)
KR20240045300A (ko)	2021-08-13	2024-04-05	알닐람 파마슈티칼스 인코포레이티드	인자 XII (F12) iRNA 조성물 및 이의 사용 방법
WO2023021046A1 (en)	2021-08-16	2023-02-23	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
EP4389892A4 (de)	2021-08-17	2025-12-10	Korea Advanced Inst Sci & Tech	Antisense-oligonukleotid zum targeting des cav3.1-gens und verwendungen davon
AU2022328698B2 (en)	2021-08-18	2025-02-20	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same
CA3228833A1 (en)	2021-08-19	2023-02-23	Neumirna Therapeutics Aps	Antisense oligonucleotides targeting adenosine kinase
WO2023034837A2 (en)	2021-08-31	2023-03-09	Alnylam Pharmaceuticals, Inc.	Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
EP4396352A4 (de)	2021-09-01	2025-10-01	Ionis Pharmaceuticals Inc	Verbindungen und verfahren zur reduzierung der dmpk-expression
WO2023034817A1 (en)	2021-09-01	2023-03-09	Entrada Therapeutics, Inc.	Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023043280A1 (ko)	2021-09-17	2023-03-23	주식회사 씨젠	합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
KR20240067943A (ko)	2021-09-24	2024-05-17	알닐람 파마슈티칼스 인코포레이티드	미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
JP2024536132A (ja)	2021-09-29	2024-10-04	エフ．ホフマン－ラロシュアーゲー	Ｒｎａ編集方法
MX2024004011A (es)	2021-10-01	2024-07-01	Adarx Pharmaceuticals Inc	Composiciones moduladoras de precalicreína y métodos de uso de estas.
MX2024004437A (es)	2021-10-15	2024-07-01	Alnylam Pharmaceuticals Inc	Composiciones de inhibidor de la angiotensina-receptor neprilisina (arni) de administracion extrahepatica y metodos de uso de las mismas.
US20250352667A1 (en)	2021-10-22	2025-11-20	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202333749A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	補體因子ｂ（ｃｆｂ）ｉｒｎａ組成物及其使用方法
JPWO2023080159A1 (de)	2021-11-02	2023-05-11
EP4426833A1 (de)	2021-11-03	2024-09-11	F. Hoffmann-La Roche AG	Oligonukleotide zur modulation der apolipoprotein e4-expression
CA3234478A1 (en)	2021-11-11	2023-05-19	Souphalone LUANGSAY	Pharmaceutical combinations for treatment of hbv
WO2023092060A1 (en)	2021-11-18	2023-05-25	Cornell University	Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023092102A1 (en)	2021-11-19	2023-05-25	Sanegene Bio Usa Inc.	Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereof
WO2023102188A1 (en)	2021-12-03	2023-06-08	Quralis Corporation	Gapmer antisense oligonucleotides with modified backbone chemistries
EP4444882A1 (de)	2021-12-07	2024-10-16	F. Hoffmann-La Roche AG	Antisense-oligonukleotide zum targeting von actl6b
GB202117758D0 (en)	2021-12-09	2022-01-26	Ucl Business Ltd	Therapeutics for the treatment of neurodegenerative disorders
EP4448106A1 (de)	2021-12-17	2024-10-23	Hoffmann-La Roche Inc.	Kombination von oligonukleotiden zur modulierung von stel1 und fubp1
EP4448763A1 (de)	2021-12-17	2024-10-23	F. Hoffmann-La Roche AG	Oligonukleotid-gba-agonisten
JP2024547071A (ja)	2021-12-20	2024-12-26	エフ．ホフマン－ラロシュアーゲー	トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
MX2024007790A (es)	2021-12-22	2024-09-06	Camp4 Therapeutics Corp	Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023131926A2 (en)	2022-01-10	2023-07-13	Ausper Biopharma Co., Ltd.	Modulation of hepatitis b virus (hbv) expression
EP4465994A1 (de)	2022-01-20	2024-11-27	Genentech, Inc.	Antisense oligonukleotide zur modulation der tmem106b-expression
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023152369A1 (en)	2022-02-14	2023-08-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
US20240167040A1 (en)	2022-02-21	2024-05-23	Hoffmann-La Roche Inc.	Antisense oligonucleotide
JPWO2023176863A1 (de)	2022-03-16	2023-09-21
KR20240161967A (ko)	2022-03-16	2024-11-13	다이이찌 산쿄 가부시키가이샤	트랜스페린 수용체 2 의 발현을 억제하는 siRNA
WO2023212625A1 (en)	2022-04-28	2023-11-02	AcuraStem Incorporated	Syf2 antisense oligonucleotides
US20240002857A1 (en)	2022-05-09	2024-01-04	Sanegene Bio Usa Inc.	Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof
CN119173632A (zh)	2022-05-10	2024-12-20	豪夫迈·罗氏有限公司	靶向cfp-elk1基因间区域的反义寡核苷酸
EP4522742A2 (de)	2022-05-13	2025-03-19	Alnylam Pharmaceuticals, Inc.	Einzelsträngige schleifenoligonukleotide
PE20250394A1 (es)	2022-05-18	2025-02-11	Hoffmann La Roche	Oligonucleotidos mejorados que actuan sobre sitios de proteina de union a arn
EP4536831A2 (de)	2022-06-10	2025-04-16	Camp4 Therapeutics Corporation	Verfahren zur modulation der progranulinexpression mit antisense-oligonukleotiden gegen regulatorische rnas
AU2023284048A1 (en)	2022-06-10	2024-11-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
CN119365600A (zh)	2022-06-17	2025-01-24	豪夫迈·罗氏有限公司	靶向颗粒蛋白前体的反义寡核苷酸
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
EP4558149A1 (de)	2022-07-21	2025-05-28	Institut National de la Santé et de la Recherche Médicale	Verfahren und zusammensetzungen zur behandlung chronischer schmerzerkrankungen
KR20250046303A (ko)	2022-08-05	2025-04-02	사네진 바이오 유에스에이 인크.	안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
EP4332221A1 (de)	2022-08-29	2024-03-06	Roche Innovation Center Copenhagen A/S	Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
EP4332239A1 (de)	2022-08-30	2024-03-06	Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.	Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
WO2024052403A1 (en)	2022-09-06	2024-03-14	F. Hoffmann-La Roche Ag	Double-stranded rna molecule for administration to the eye
JP2025532593A (ja)	2022-09-15	2025-10-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
WO2024073042A1 (en)	2022-09-30	2024-04-04	Entrada Therapeutics, Inc.	Ocular delivery of therapeutic agents
JP2025532985A (ja)	2022-09-30	2025-10-03	アルナイラムファーマシューティカルズ，インコーポレイテッド	修飾二本鎖ｒｎａ剤
CN120265773A (zh)	2022-10-14	2025-07-04	美国圣因生物股份有限公司	靶向c3的小干扰rna及其用途
WO2024098061A2 (en)	2022-11-04	2024-05-10	Genkardia Inc.	Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024104914A1 (en)	2022-11-14	2024-05-23	BioNTech SE	Rna capping efficiency assay
AU2022486981A1 (en)	2022-11-22	2025-06-12	Quantdetect, Inc.	Probe/primer library for diagnosis of cancer
AU2023403208A1 (en)	2022-12-01	2025-06-19	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2024126654A1 (en)	2022-12-14	2024-06-20	F. Hoffmann-La Roche Ag	Antisense oligonucleotides targeting actl6b
EP4638743A2 (de)	2022-12-19	2025-10-29	Sanegene Bio USA Inc.	Auf cfb abzielende kleine interferierende rna und verwendungen davon
EP4646478A1 (de)	2023-01-06	2025-11-12	Institut National de la Santé et de la Recherche Médicale	Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
WO2024155986A2 (en)	2023-01-20	2024-07-25	AcuraStem Incorporated	Unc13a antisense oligonucleotides
EP4658281A1 (de)	2023-01-30	2025-12-10	Vib Vzw	Suppressoren von tauopathien
AU2024215901A1 (en)	2023-01-31	2025-07-24	AcuraStem Incorporated	Syf2 antisense oligonucleotides
AU2024213258A1 (en)	2023-01-31	2025-06-26	Seqirus Inc.	Capping assay
KR20250143312A (ko)	2023-02-06	2025-10-01	아큐라스템 인코포레이티드	Pikfyve 안티센스 올리고뉴클레오타이드
EP4662311A2 (de)	2023-02-09	2025-12-17	Alnylam Pharmaceuticals, Inc.	Reversirmoleküle und verfahren zu ihrer verwendung
JP2026507051A (ja)	2023-02-21	2026-02-27	ブイアイビーブイゼットダブリュ	シナプトギリン－３発現を調節するためのオリゴヌクレオチド
WO2024175586A2 (en)	2023-02-21	2024-08-29	Vib Vzw	Inhibitors of synaptogyrin-3 expression
WO2024175707A1 (en)	2023-02-22	2024-08-29	Helmholtz-Zentrum für Infektionsforschung GmbH	A synthetic oligonucleotide for treating nidovirales infections
US20240309383A1 (en)	2023-02-24	2024-09-19	Suzhou Sanegene Bio Inc.	Small interfering rna targeting hbv and uses thereof
WO2024186673A2 (en)	2023-03-03	2024-09-12	Sanegene Bio Usa Inc.	Small interfering rna targeting apoc3 and uses thereof
AU2024254919A1 (en)	2023-04-12	2025-10-30	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery of double-stranded rna agents
WO2024220930A2 (en)	2023-04-20	2024-10-24	Adarx Pharmaceuticals, Inc.	Mapt-modulating compositions and methods of use thereof
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
EP4450626A1 (de)	2023-04-21	2024-10-23	IFOM - Istituto Fondazione di Oncologia Molecolare ETS	Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
CN121263524A (zh)	2023-05-04	2026-01-02	豪夫迈·罗氏有限公司	能够上调葡糖脑苷脂酶表达的寡核苷酸
WO2024231285A1 (en)	2023-05-05	2024-11-14	BioNTech SE	Method of analysing contaminants in rna products by ion-pair chromatography
CN121398851A (zh)	2023-05-12	2026-01-23	阿达尔克斯制药有限公司	Nmda配体缀合的化合物及其用途
WO2024238385A2 (en)	2023-05-12	2024-11-21	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2024243062A1 (en)	2023-05-19	2024-11-28	Streck Llc	Detection of antibiotic resistance genes
IL324720A (en)	2023-05-26	2026-01-01	Adarx Pharmaceuticals Inc	SOD1 modulators and methods of using them
AU2024304484A1 (en)	2023-06-14	2026-02-05	Sanofi Pasteur Inc.	Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger rna
TW202511485A (zh)	2023-06-16	2025-03-16	日商住友製藥股份有限公司	調節ｒｐｓ２５基因之表現及／或其功能的反義寡核苷酸
TW202516004A (zh)	2023-06-16	2025-04-16	瑞士商赫孚孟拉羅股份公司	調節ｊａｋ１表現之雙股寡核苷酸
CN121712891A (zh)	2023-06-20	2026-03-20	阿达尔克斯制药有限公司	Lrrk2调节组合物及其使用方法
CN121866332A (zh)	2023-06-21	2026-04-14	美国圣因生物股份有限公司	靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
WO2025008406A1 (en)	2023-07-04	2025-01-09	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of cancer
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
AU2024299328A1 (en)	2023-07-21	2026-01-22	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
WO2025015676A1 (zh) *	2023-07-21	2025-01-23	瑞孚医药科技（广州）有限公司	碳环核苷、寡核苷酸及其制备方法和医药用途
WO2025023659A1 (ko)	2023-07-25	2025-01-30	주식회사 씨젠	타겟 핵산 서열에 대한 올리고뉴클레오타이드 서열의 얼라인먼트 정보를 제공하는 컴퓨터-구현 방법
AU2024299627A1 (en)	2023-07-25	2026-01-22	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
TW202519653A (zh)	2023-07-25	2025-05-16	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	Ｃａｓ內切酶及相關方法
KR20260049597A (ko)	2023-08-04	2026-04-14	알닐람 파마슈티칼스 인코포레이티드	Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
IL326646A (en)	2023-08-17	2026-04-01	Entrada Therapeutics Inc	Intracellular targeting of oligonucleotides
WO2025038901A1 (en)	2023-08-17	2025-02-20	Entrada Therapeutics, Inc.	Cyclic peptides for delivering therapeutics
EP4512899A1 (de)	2023-08-23	2025-02-26	Lipigon Pharmaceuticals AB	Angptl4-aso-zusammensetzungen zur behandlung von atherosklerose bei menschen
TW202523839A (zh)	2023-08-25	2025-06-16	學校法人福岡大學	導入有磷酸部修飾之穩定型標靶編輯引導ｒｎａ
WO2025047953A1 (ja)	2023-08-30	2025-03-06	株式会社Stratoimmune	ＲａｓＧＲＰ４のアンチセンスオリゴヌクレオチド
WO2025061842A1 (en)	2023-09-19	2025-03-27	Charité - Universitätsmedizin Berlin	Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
WO2025064660A2 (en)	2023-09-21	2025-03-27	Alnylam Pharmaceuticals, Inc.	Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025072246A1 (en)	2023-09-26	2025-04-03	Entrada Therapeutics, Inc.	Compounds and methods for skipping exon 50 in duchenne muscular dystrophy
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
US20250115914A1 (en)	2023-10-04	2025-04-10	Lemba Bv	Compounds for inhibition of il-1beta expression
US20250115909A1 (en)	2023-10-04	2025-04-10	Lemba Bv	Compounds for inhibiting amanzi
CN121909203A (zh)	2023-10-31	2026-04-21	科罗生物公司	包含氨基磷酸酯核苷酸间键的寡核苷酸
TW202540417A (zh)	2023-11-10	2025-10-16	美商英特利亞醫療公司	用於基因體編輯之組合物、方法及系統
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025132962A2 (en)	2023-12-21	2025-06-26	F. Hoffmann-La Roche Ag	Antisense oligonucleotide
US20250263702A1 (en)	2024-02-19	2025-08-21	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025228441A2 (en)	2024-04-30	2025-11-06	Sanegene Bio Usa Inc.	Small interfering rna targeting inhbe and uses thereof
WO2025237990A1 (en)	2024-05-14	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025252669A1 (en)	2024-06-03	2025-12-11	Evotec International Gmbh	Modified oligonucleotides for reducing atxn3 expression
WO2025255388A1 (en)	2024-06-05	2025-12-11	Camp4 Therapeutics Corporation	Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006436A1 (en)	2024-06-25	2026-01-02	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
WO2026006390A2 (en)	2024-06-26	2026-01-02	Intellia Therapeutics, Inc.	Modified guide rnas for genome editing
WO2026017140A2 (en)	2024-07-18	2026-01-22	Sanegene Bio Usa Inc.	Small interfering rna targeting fxi and uses thereof
WO2026041067A2 (en)	2024-08-20	2026-02-26	Sanegene Bio Usa Inc.	Small interfering rna targeting myostatin (mstn) and uses thereof
WO2026041784A1 (en)	2024-08-23	2026-02-26	Vib Vzw	Oligonucleotides for modulating synaptogyrin-3 expression
WO2026046411A1 (en)	2024-09-02	2026-03-05	Sanegene Bio Usa Inc.	Small interfering rna targeting plasminogen (plg) and uses thereof
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026052826A1 (en)	2024-09-09	2026-03-12	Roche Diagnostics Gmbh	Methods for producing fluorescent dyes
EP4711455A1 (de)	2024-09-11	2026-03-18	Aarhus Universitet	Oligonukleotid aus kleiner künstlicher rna (smartrna) zur modulation der proteinexpression
WO2026061986A1 (en)	2024-09-17	2026-03-26	Institut National de la Santé et de la Recherche Médicale	Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026062247A1 (en)	2024-09-20	2026-03-26	Astrazeneca Ab	Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a protecting group
WO2026068729A1 (en)	2024-09-26	2026-04-02	Neumirna Therapeutics Aps	Antimir-27b for treatment of parkinson's disease
WO2026080323A1 (en)	2024-10-09	2026-04-16	Quralis Corporation	Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1223831A (en) *	1982-06-23	1987-07-07	Dean Engelhardt	Modified nucleotides, methods of preparing and utilizing and compositions containing the same
EP0472648A4 (en) *	1989-05-18	1992-09-16	Microprobe Corporation	Crosslinking oligonucleotides
US5177196A (en) *	1990-08-16	1993-01-05	Microprobe Corporation	Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DE4408528A1 (de)	1994-03-14	1995-09-28	Hoechst Ag	Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
HUT76094A (en) *	1994-03-18	1997-06-30	Lynx Therapeutics	Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
DK0820483T3 (da)	1995-04-07	2001-01-02	Mogens Havsteen Jakobsen	Fremgangsmåde til fotokemisk immobilisering af ligander under anvendelse af quinoner
US6153745A (en) *	1995-09-22	2000-11-28	Amersham Pharmacia Biotech Uk Limited	Relating to mutagenesis of nucleic acids
JP2002515738A (ja) *	1996-01-23	2002-05-28	アフィメトリックス，インコーポレイティド	核酸分析法
JP3781879B2 (ja) *	1996-11-18	2006-05-31	武今西	新規ヌクレオチド類縁体
JP3756313B2 (ja) *	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体

1998
- 1998-09-14 AU AU90633/98A patent/AU9063398A/en not_active Abandoned
- 1998-09-14 EP EP10185908A patent/EP2341058A3/de not_active Withdrawn
- 1998-09-14 DE DE69829760.1T patent/DE69829760T3/de not_active Expired - Lifetime
- 1998-09-14 CN CNB988109557A patent/CN1273476C/zh not_active Expired - Lifetime
- 1998-09-14 AT AT98942516T patent/ATE293123T1/de not_active IP Right Cessation
- 1998-09-14 JP JP2000511775A patent/JP4236812B2/ja not_active Expired - Lifetime
- 1998-09-14 NZ NZ503765A patent/NZ503765A/en not_active IP Right Cessation
- 1998-09-14 EP EP98942516.0A patent/EP1015469B2/de not_active Expired - Lifetime
- 1998-09-14 DE DE04020014T patent/DE04020014T1/de active Pending
- 1998-09-14 ES ES98942516.0T patent/ES2242291T5/es not_active Expired - Lifetime
- 1998-09-14 EP EP04020014A patent/EP1557424A1/de not_active Withdrawn
- 1998-09-14 CA CA2303299A patent/CA2303299C/en not_active Expired - Lifetime
- 1998-09-14 WO PCT/DK1998/000393 patent/WO1999014226A2/en not_active Ceased
- 1998-09-14 EP EP10161457A patent/EP2253639A1/de not_active Withdrawn
- 1998-09-14 IL IL13500098A patent/IL135000A0/xx unknown
- 1998-09-14 KR KR10-2000-7002608A patent/KR100414936B1/ko not_active Expired - Lifetime
- 1998-09-14 EP EP10185895A patent/EP2341057A3/de not_active Withdrawn
2000
- 2000-03-09 IL IL135000A patent/IL135000A/en not_active IP Right Cessation
2007
- 2007-05-07 JP JP2007122900A patent/JP5677716B2/ja not_active Expired - Lifetime
- 2007-08-28 IL IL185570A patent/IL185570A/en not_active IP Right Cessation
- 2007-08-28 IL IL185569A patent/IL185569A/en not_active IP Right Cessation
- 2007-08-28 IL IL185568A patent/IL185568A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2242291T3 (es)	2005-11-01
IL185570A0 (en)	2008-01-06
HK1033946A1 (en)	2001-10-05
JP5677716B2 (ja)	2015-02-25
IL185570A (en)	2012-02-29
CN1273476C (zh)	2006-09-06
DE69829760T2 (de)	2006-03-02
EP1015469A2 (de)	2000-07-05
IL135000A (en)	2011-11-30
EP2341057A2 (de)	2011-07-06
EP1557424A1 (de)	2005-07-27
EP1015469B1 (de)	2005-04-13
AU9063398A (en)	1999-04-05
IL185568A (en)	2011-11-30
WO1999014226A3 (en)	1999-08-05
EP2253639A1 (de)	2010-11-24
IL135000A0 (en)	2001-05-20
DE69829760T3 (de)	2016-04-14
CA2303299C (en)	2016-02-23
EP1015469B2 (de)	2015-11-18
IL185569A0 (en)	2008-01-06
EP2341058A2 (de)	2011-07-06
JP2002521310A (ja)	2002-07-16
IL185569A (en)	2012-02-29
NZ503765A (en)	2002-04-26
CA2303299A1 (en)	1999-03-25
WO1999014226A2 (en)	1999-03-25
DE69829760D1 (de)	2005-05-19
JP2007211025A (ja)	2007-08-23
CN1279687A (zh)	2001-01-10
JP4236812B2 (ja)	2009-03-11
DE04020014T1 (de)	2006-01-26
KR100414936B1 (ko)	2004-01-13
EP2341058A3 (de)	2011-11-23
ES2242291T5 (es)	2016-03-11
KR20010030586A (ko)	2001-04-16
EP2341057A3 (de)	2011-11-23
IL185568A0 (en)	2008-01-06

Legal Events

Date	Code	Title	Description
2005-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE293123T1 (de)	2005-04-15	Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
EP1470144B1 (de)	2008-12-03	Oligonukleotide mit alternierenden segmenten und deren verwendungen
Lesnik et al.	1993	Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA: RNA duplexes
EP0963997A4 (de)	2000-11-29	Nucleotidanaloga
CA2504234C (en)	2011-09-13	Process for amplifying nucleic acids
JP2005517432A5 (de)	2005-12-15
AU2003202376A1 (en)	2003-09-18	Oligonucleotides comprising alternating segments and uses thereof
Prakash et al.	2004	2 ‘-O-[2-(Guanidinium) ethyl]-modified oligonucleotides: stabilizing effect on duplex and triplex structures
EP0977767A4 (de)	2003-04-23	Aminooxy-modifizierte oligonukleotide
JPH06511492A (ja)	1994-12-22	キラルリン結合を有するオリゴヌクレオチド
Shuman et al.	1993	Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA.
WO2018057946A2 (en)	2018-03-29	Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
KR20010073140A (ko)	2001-07-31	Ｄｎａ 의 합성방법
EP1171634A4 (de)	2002-07-31	Amplifikation und sequenzierung von primer-paaren und deren verwendung
ATE242261T1 (de)	2003-06-15	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
Jestrabova et al.	2023	Arylethynyl-or Alkynyl-Linked Pyrimidine and 7-Deazapurine 2′-Deoxyribonucleoside 3′-Phosphoramidites for Chemical Synthesis of Hypermodified Hydrophobic Oligonucleotides
EP3286331B1 (de)	2022-12-14	Verfahren zur hybridisierung eines nukleinsäuremoleküls
Nevinsky et al.	1995	High affinity interaction of mammalian DNA topoisomerase I with short single-and double-stranded oligonucleotides
WO2001023618A3 (en)	2002-04-18	Compositions and methods for reducing oligonucleotide hybridization and priming specificity
WO1993005176A1 (en)	1993-03-18	Improvements in oligonucleotide primers and probes
Yamakawa et al.	1996	Properties and anti-HIV activity of nicked dumbbell oligonucleotides
ATE332981T1 (de)	2006-08-15	Einzelsträngige oligonukleotide, sonden, primer und ein vefahren zur detektion von spirochaeten
Saito-Tarashima et al.	2018	Four-Hydrogen-Bonding Base Pairs in Oligonucleotides: Design, Synthesis, and Properties
Aoyagi et al.	1996	Nucleosides and Nucleotides. 153. Effects of 2′-α-and 2′-β-Bromo-2′-deoxyadenosine on Oligonucleotide Hybridization and Nuclease Stability
EP1221491A4 (de)	2003-04-16	System und verfahren zum sequenzieren genetischer substanzen